Life Glow Plus Super Life Glow Life Glow Basic Bone Dense Calcium Taheebo Life Tea Germanium Colloidal Minerals Methyl Sulfonyl Methane Transfer Factor Immune Egg	Vibrant Life Home Web All VL Products Family Of Three Chelation Formulas Oral Chelation Ingredient Comparisons The Wednesday Letter Karl Loren Viewpoints Frequently Asked Questions Testimonials Free Radicals Central Page For 18 Web Sites	Vibrant Life Home Page Shopping Cart	Separate Search Page or search below
Navigation Help	Karl Loren Background	Ingredients Technical	Write To Karl Loren	Table Of Contents

Methionine

Here are scientific studies relating to the amino acid methionine, and its cousin, S-adenosyl-L-methionine.

Top

SUBSCRIBE:  The Wednesday Letter is a free electronic monthly newsletter written and published by Karl Loren.  You can view more than 50 back issues of this publication by clicking here.  The Wednesday Letter subscription list is maintained on a secure server, no name is ever given or sold to anyone, and it is never used except for this Newsletter.  It is automatically published on the Tuesday night just before the first Wednesday of every month.  You can subscribe to this free monthly electronic letter by entering your eMail address and name below.  You will then automatically receive a request for confirmation, sent to whatever address you have entered.  If you do NOT receive this confirmation request, then you will not be subscribed.  There may have been an error with your address and you should resubmit.  The letter is never sent twice to the same address -- so you do not have to worry about a duplicate subscription.  When you receive this confirmation request you must reply to it, or your subscription will not become active.  No one can subscribe your name, and address, without you being notified, and if you get an unwanted notice of subscription you only need to DO NOTHING and the subscription will NOT be active.

REMOVAL:  You can remove yourself from the subscription list in several different ways.  Click here to read about this entire newsletter system.  Every edition of The Wednesday Letter is delivered to your address with YOUR name and address in view on the letter, with a link that allows you to remove THAT name from the subscription list.  If you try to send this removal message from an address different from the one you used to send in your original confirmation, then you will get a warning notice first, sent to the subscription address, asking you to confirm that you want to be removed from the list -- by replying to THAT request for confirmation, you will then be automatically removed.  Thus, no one else can unsubscribe you, from some other computer, without your knowledge.  But, if you send in the unsubscribe notice from the same machine used to receive the Letter, then the removal from the subscription list is automatic.

Personal Message:  When you send a personal message to Karl Loren, you will receive a personal reply as per his instructions.  Karl pledges that every personal message will get a personal answer. When you provide your mail address, we will send you free information including our free catalog and a cassette tape lecture by Karl Loren about heart disease, no charge, by mail, even if outside the US.  You can select particular information you would like to receive, along with the free cassette tape and catalog.

You can reach Vibrant Life in many ways, including by mail to Vibrant Life, 2808 N. Naomi St., Burbank, CA 91504.  Within the US and Canada, use the toll free number:  (800) 523-4521, the local number:  (818) 558-1799, the FAX:  (818) 558-7299, eMail to kimberly@oralchelation.com or any one of the hundreds of message forms throughout the 50 web sites.  Vibrant Life normally ships the same day we get an order.  There are message forms on each of the 100,000+ pages on this and other sites where you can communicate with Vibrant Life.  Check out our companion site, at:  http://www.oralchelation.net where Karl's 2000 page book is published.  Karl Loren is the author and webmaster for this BOOK, as well as for another web site about ORAL CHELATION.  His personal philosophical articles are at PHILOSOPHY. 

Copyright © May 20, 2008 6:24 AM by Karl Loren on behalf of Vibrant Life, ALL RIGHTS RESERVED.  Permission is granted for non-commercial downloading, copying, distribution or redistribution on two conditions:  One, that some form of copyright notice is included in every copy distributed or copied, showing the copyright belonging to Vibrant Life, Burbank, CA, at www.oralchelation.com . The second condition is that the material is not to be used for any purpose contrary to the purposes and objectives of this site.  This permission does not extend to materials on this site which are copyrighted by others.

Click here to add the Wednesday Letter as a Channel on your desktop.   If your browser is so-equipped, you will be guided through a series of simple questions (about subscription information).  Depending on your choices you can show the Vibrant Life Wednesday Letter as one of your "active channels" which will automatically download the new Wednesday Letter every month.  In this way you can have the Wednesday Letter delivered to your desktop during the night (or your schedule) for immediate viewing in your browser.  You can turn on or off this channel, at will, and delete the channel from your desktop at any time.  With this feature operating you can click on the Wednesday Letter channel at any time to read the most recent copy of this electronic letter.

You can reach Vibrant Life in many ways, including by mail to Vibrant Life, 2808 N. Naomi St., Burbank, CA 91504.  Within the US and Canada, use the toll free number:  (800) 523-4521, the local number:  (818) 558-1799, the FAX:  (818) 558-7299, eMail to kimberly@oralchelation.com or any one of the hundreds of message forms throughout the 50 web sites.  Vibrant Life normally ships the same day we get an order.  There are message forms on each of the 100,000+ pages on this and other sites where you can communicate with Vibrant Life.  Check out our companion site, at:  http://www.oralchelation.net where Karl's 2000 page book is published.  Karl Loren is the author and webmaster for this BOOK, as well as for another web site about ORAL CHELATION.  His personal philosophical articles are at PHILOSOPHY. 

Copyright © May 20, 2008 6:24 AM by Karl Loren on behalf of Vibrant Life, ALL RIGHTS RESERVED.  Permission is granted for non-commercial downloading, copying, distribution or redistribution on two conditions:  One, that some form of copyright notice is included in every copy distributed or copied, showing the copyright belonging to Vibrant Life, Burbank, CA, at www.oralchelation.com . The second condition is that the material is not to be used for any purpose contrary to the purposes and objectives of this site.  This permission does not extend to materials on this site which are copyrighted by others.

Click here to add the Wednesday Letter as a Channel on your desktop.   If your browser is so-equipped, you will be guided through a series of simple questions (about subscription information).  Depending on your choices you can show the Vibrant Life Wednesday Letter as one of your "active channels" which will automatically download the new Wednesday Letter every month.  In this way you can have the Wednesday Letter delivered to your desktop during the night (or your schedule) for immediate viewing in your browser.  You can turn on or off this channel, at will, and delete the channel from your desktop at any time.  With this feature operating you can click on the Wednesday Letter channel at any time to read the most recent copy of this electronic letter.

You can reach Vibrant Life in many ways, including by mail to Vibrant Life, 2808 N. Naomi St., Burbank, CA 91504.  Within the US and Canada, use the toll free number:  (800) 523-4521, the local number:  (818) 558-1799, the FAX:  (818) 558-7299, eMail to kimberly@oralchelation.com or any one of the hundreds of message forms throughout the 50 web sites.  Vibrant Life normally ships the same day we get an order.  There are message forms on each of the 100,000+ pages on this and other sites where you can communicate with Vibrant Life.  Check out our companion site, at:  http://www.oralchelation.net where Karl's 2000 page book is published.  Karl Loren is the author and webmaster for this BOOK, as well as for another web site about ORAL CHELATION.  His personal philosophical articles are at PHILOSOPHY. 

Copyright © May 20, 2008 6:24 AM by Karl Loren on behalf of Vibrant Life, ALL RIGHTS RESERVED.  Permission is granted for non-commercial downloading, copying, distribution or redistribution on two conditions:  One, that some form of copyright notice is included in every copy distributed or copied, showing the copyright belonging to Vibrant Life, Burbank, CA, at www.oralchelation.com . The second condition is that the material is not to be used for any purpose contrary to the purposes and objectives of this site.  This permission does not extend to materials on this site which are copyrighted by others.

HealthGate Documents

Record 1 from database: MEDLINE
Return To The Top

Title

The biochemistry of endogenous organosulphur compounds.

Author

James SP

Address

School of Biochemistry, University of Birmingham, UK.

Source

Drug Metabol Drug Interact, 1988, 6:3-4, 167-82

Abstract

The role and metabolism of methionine and cysteine in mammals are described. An outline of the history of glutathione, of its function in maintaining the thiol status of the cell and of its protective action against oxidative stress, is given. The importance of glutathione reductase, glutathione peroxidases, glutathione-S-transferases in endogenous metabolism and of gamma-glutamyltranspeptidase is described. The relationship between cysteine and glutathione is considered together with the inter-organ translocation of glutathione and its metabolism.

Language of Publication

English

Unique Identifier

90151143

MeSH Heading (Major)

Cysteine|*ME; Glutathione|*ME; Methionine|*ME; Sulfur|*ME

MeSH Heading

Animal; Human

Publication Type

JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

ISSN

0792-5077

Country of Publication

ENGLAND

CAS Registry/EC Number

4371-52-2 (Cysteine); 70-18-8 (Glutathione); 7005-18-7 (Methionine); 7704-34-9 (Sulfur)

Record 2 from database: MEDLINE
Return To The Top

Title

Methioninase: a therapeutic for diseases related to altered methionine metabolism and transmethylation: cancer, heart disease, obesity, aging, and Parkinson's disease.

Author

Hoffman RM

Address

AntiCancer, Incorporated, San Diego, CA 92111, USA. all@anticancer.com

Source

Hum Cell, 1997 Mar, 10:1, 69-80

Abstract

Methionine metabolism and transmethylation are central to the metabolism and differentiation of all known cells. In enkaryotic organisms, methionine metabolism and transmethylation are of paramount importance in modification and regulation of proteins, lipids, and nucleic acids. The differential methylation of genes regulates their expression in the myriad of cells in eukaryotic organisms. Disruption and abnormalities in methionine metabolism and transmethylation seems to be associated with the major diseases of mankind, including cancer, heart disease, aging, obesity, and Parkinson's disease. In this review, we describe how aberrant and abnormal methionine metabolism and transmethylation are related to these major diseases. Most importantly, we review and hypothesize how the developing therapeutic recombination methioninase (rMETase) can be utilized to cure or prevent all of these diseases.

Language of Publication

English

Unique Identifier

97378448

MeSH Heading (Major)

Aging|*/ME; Heart Diseases|*ET; Methionine|*ME; Neoplasms|DT/*ET/ME; Obesity|*ET; Parkinson Disease|*ET; Sulfhydrases|PD/*TU

MeSH Heading

Animal; Drug Interactions; Drug Therapy, Combination; Human; Methylation; Recombinant Proteins|PD/TU

Publication Type

JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

ISSN

0914-7470

Country of Publication

JAPAN

CAS Registry/EC Number

EC 4.4. (Sulfhydrases); EC 4.4.1.11 (L-methionine gamma-lyase); 0 (Recombinant Proteins); 7005-18-7 (Methionine)

Record 3 from database: MEDLINE
Return To The Top

Title

Methionine metabolism: a window on carcinogenesis?

Author

Gatton-Umphress TL; Weber KA; Seidler NW

Address

University of Health Sciences, Kansas City, Mo.

Source

Hosp Pract (Off Ed), 1993 Sep 30, 28:9A, 83-5, 89-90

Abstract

Recent experimental evidence links changes in methionine metabolism to the onset and progression of cancer. Aberrant methylation reactions and polyamine synthesis may alter genome stability, gene expression, and cell proliferation.

Language of Publication

English

Unique Identifier

94013160

MeSH Heading (Major)

Methionine|*ME; Neoplasms|DI/*ET/ME

MeSH Heading

Cell Transformation, Neoplastic|ME; DNA Damage; DNA Repair; Human; Oncogene Proteins|ME

Publication Type

JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

ISSN

8750-2836

Country of Publication

UNITED STATES

CAS Registry/EC Number

0 (Oncogene Proteins); 7005-18-7 (Methionine)

Record 4 from database: MEDLINE
Return To The Top

Title

Methionine sulfoxide and the oxidative regulation of plasma proteinase inhibitors.

Author

Swaim MW; Pizzo SV

Address

Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710.

Source

J Leukoc Biol, 1988 Apr, 43:4, 365-79

Abstract

The sensitivity of methionine residues to oxidation is a mechanism by which many proteins, including plasma proteinase inhibitors, may be oxidatively inactivated. Much evidence suggests that methionine oxidation and concurrent losses of protein activity not only occur widely in living systems but are physiologic, homeostatic processes. Neutrophils, macrophages and other leukocytes secrete large quantities of powerful oxidants at sites of inflammation and may readily bring about methionine oxidative inactivation of proteins. In particular, oxidation of proteinase inhibitors may favorably alter the proteinase-antiproteinase balance to facilitate tissue remodeling and protection from invading organisms. Leukocyte-mediated inhibitor oxidation also appears to regulate local immunosuppressive activity. Pathophysiologic processes such as emphysema and rheumatoidal disease involve derangements of these homeostatic mechanisms.

Language of Publication

English

Unique Identifier

88171127

MeSH Heading (Major)

Methionine|*AA/ME; Peptide Peptidohydrolases|*BL; Protease Inhibitors|*BL

MeSH Heading

alpha 1-Antitrypsin|BL; alpha-Macroglobulins|ME; Animal; Binding Sites; Human; Leukocytes|EN; Oxidation-Reduction; Smoke; Trypsin Inhibitors|BL/ME

Publication Type

JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

ISSN

0741-5400

Country of Publication

UNITED STATES

CAS Registry/EC Number

EC 3.4.- (Peptide Peptidohydrolases); 0 (alpha 1-Antitrypsin); 0 (alpha-Macroglobulins); 0 (Protease Inhibitors); 0 (Trypsin Inhibitors); 454-41-1 (methionine sulfoxide); 7005-18-7 (Methionine)

Record 5 from database: MEDLINE
Return To The Top

Title

PET for diagnosis of malignant lymphoma of the scalp: comparison of [11C]methyl-L-methionine and [18F]fluoro-2-deoxygluc ose.

Author

Tsuyuguchi N; Hakuba A; Okamura T; Ochi H; Suzuki T; Sunada I

Address

Department of Neurosurgery, Osaka City University Medical School, Japan.

Source

J Comput Assist Tomogr, 1997 Jul-Aug, 21:4, 590-3

Abstract

A 43-year-old woman was admitted with a tumor mass in her forehead. Two months previously, a lump in her breast had been diagnosed as mastopathy. Palpation revealed an elastically hard immobile tumor mass in her forehead. MRI detected a tumoral lesion of generally uniform contrast involving frontal subcutaneous, cranial, and intracranial regions. PET demonstrated more intensive and wider accumulation of [11C]methyl-L-methionine (Met) than of [18F]fluoro-2-deoxyglucose (FDG). Biopsy of the forehead mass was performed, which was diagnosed as B-cell-type malignant lymphoma. The tumor mass in the forehead then shrank spontaneously, as confirmed by palpation and MRI. The tumor mass in the left breast was totally extirpated and histologically diagnosed as B-cell-type malignant lymphoma, like the tumor mass in the forehead. Postoperatively, chemotherapy (VEPA) was performed. Although FDG accumulation had not been detected, postchemotherapy PET demonstrated slight Met accumulation, suggesting the presence of a residual tumor. PET served well to detect the lesion and evaluate therapeutic efficacy in malignant lymphoma. Met-PET was more sensitive to malignant lymphoma than FDG-PET.

Language of Publication

English

Unique Identifier

97359847

MeSH Heading (Major)

Carbon Radioisotopes|*DU; Deoxyglucose|*AA/DU; Fluorine Radioisotopes|*DU; Lymphoma|*RI/TH; Methionine|*AA/DU; Scalp|PA/RA/*RI; Skin Neoplasms|*RI/TH; Tomography, Emission-Computed|*MT

MeSH Heading

Adult; Case Report; Combined Modality Therapy; Comparative Study; Female; Human; Magnetic Resonance Imaging; Tomography, X-Ray Computed

Publication Type

JOURNAL ARTICLE; REVIEW; REVIEW OF REPORTED CASES

ISSN

0363-8715

Country of Publication

UNITED STATES

CAS Registry/EC Number

0 (Carbon Radioisotopes); 0 (Fluorine Radioisotopes); 10332-17-9 (methionine methyl ester); 154-17-6 (Deoxyglucose); 29702-43-0 (fludeoxyglucose F 18); 7005-18-7 (Methionine)

Record 6 from database: MEDLINE
Return To The Top

Title

Functional methionine synthase deficiency (cblE and cblG): clinical and biochemical heterogeneity.

Author

Watkins D; Rosenblatt DS

Address

Centre for Human Genetics, McGill University, Montreal, Quebec, Canada.

Source

Am J Med Genet, 1989 Nov, 34:3, 427-34

Abstract

Functional methionine synthase deficiency is generally characterized by homocystinuria and hypomethioninemia in the absence of methylmalonic aciduria. Patients are divided into two classes, cblE and cblG, on the basis of complementation analysis. Presentation has usually been in the first 2 years of life, but one patient came to medical attention at age 21 years with symptoms initially diagnosed as multiple sclerosis. Common findings among 11 patients (4 with cblE and 7 with cblG) have included megaloblastic anemia (all patients) and various neurological deficits including developmental retardation (10 patients), cerebral atrophy (8 patients), hypotonia (7 patients), EEG abnormalities (6 patients), and nystagmus (5 patients). Hypertonia, seizures, blindness, and ataxia were less frequent. All patients have responded to therapy with cobalamin with resolution of anemia and biochemical abnormalities; neurological deficits resolved more slowly and in some cases incompletely. Hydroxycobalamin has been more effective than cyanocobalamin. Fibroblasts from patients with cblE (5 patients) and cblG (6 patients) all showed decreased intracellular levels of methylcobalamin (MeCbl) and decreased incorporation of label from 5-methyltetrahydrofolate into macromolecules, suggesting decreased activity of the MeCbl-dependent enzyme methionine synthase. Methionine synthase specific activity in extracts of all cblE fibroblasts was normal or near-normal under standard reducing conditions; synthase specific activity in extracts of 5 cblG patients was low but was high in a 6th patient measured in another laboratory. Thus, there is heterogeneity among patients with functional methionine synthase deficiency both in clinical presentation and in the results of biochemical studies of cultured cells.

Language of Publication

English

Unique Identifier

90086914

MeSH Heading (Major)

Homocystinuria|*EN/GE; Methionine|BL/*DF; Methyltransferases|*DF; Tetrahydropteroylglutamate Methyltransferase|*DF/GE; Vitamin B 12|*AA/BL/TU

MeSH Heading

Adult; Anemia, Megaloblastic|ET; Cells, Cultured; Female; Fibroblasts|EN; Genetic Complementation Test; Human; Infant; Infant, Newborn; Male; Nervous System Diseases|ET; Support, Non-U.S. Gov't

Publication Type

JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

ISSN

0148-7299

Country of Publication

UNITED STATES

CAS Registry/EC Number

EC 2.1.1. (Methyltransferases); EC 2.1.1.13 (Tetrahydropteroylglutamate Methyltransferase); 13422-55-4 (mecobalamin); 68-19-9 (Vitamin B 12); 7005-18-7 (Methionine)

Record 7 from database: MEDLINE
Return To The Top

Title

Plasma homocysteine and methionine tolerance in early-onset vascular disease.

Author

Brattström L; Israelsson B; Hultberg B

Address

Department of Neurology, University Hospital, Lund, Sweden.

Source

Haemostasis, 1989, 19 Suppl 1:, 35-44

Abstract

In three different studies we tested the hypothesis that early-onset vascular disease is associated with impaired homocysteine metabolism which could contribute to the development of arteriosclerosis and thrombosis. In patients with occlusive vascular disease before the age of 60, a post-methionine load increase of plasma homocysteine exceeding the highest value for comparable healthy control subjects was found in 1 of 21 with myocardial infarction (5%), 14 of 37 with aorto-iliac disease (38%), and 17 of 53 with cerebrovascular disease (32%). This might indicate heterozygosity for homocystinuria due to cystathionine beta-synthase deficiency. Concentrations of serum vitamin B12 and red cell folate had an important modulating effect on plasma homocysteine concentrations in the fasting state.

Language of Publication

English

Unique Identifier

90034427

MeSH Heading (Major)

Homocysteine|*BL; Methionine|*PK; Vascular Diseases|*BL

MeSH Heading

Drug Tolerance; Human; Risk Factors

Publication Type

JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

ISSN

0301-0147

Country of Publication

SWITZERLAND

CAS Registry/EC Number

454-28-4 (Homocysteine); 7005-18-7 (Methionine)

Record 8 from database: MEDLINE
Return To The Top

Title

The influence of ethanol on hepatic transmethylation.

Author

Barak AJ; Beckenhauer HC

Address

Liver Study Unit, Veterans Administration Medical Center, Omaha, NE 68105.

Source

Alcohol Alcohol, 1988, 23:1, 73-7

Abstract

One of the most important biochemical pathways in the organism is the biosynthesis of methionine from the methylation of homocysteine. Two different reactions are responsible for this methylation, one utilizing N5-methyltetra-hydrofolate as a methylating agent and the other using betaine as the methyl donor. This paper reviews some recent findings in this laboratory, which demonstrate that ethanol-feeding to rats impairs the folate-induced reaction. Our findings also show that this impairment is compensated for through the adaptive increase in the enzyme using betaine in the biosynthesis of methionine. Further studies indicate that the mechanism of action in the impairment may occur through the formation of individual adducts between the folate-induced enzyme (methionine synthetase), its essential cofactors and acetaldehyde, a metabolic product of ethanol. These findings suggest a basis for why rats are more resistant to alcoholic liver injury than humans and may offer a means of protecting against alcoholic liver injury in man.

Language of Publication

English

Unique Identifier

88192777

MeSH Heading (Major)

Alcohol, Ethyl|*PD; Liver|*DE; Methionine|*ME

MeSH Heading

Animal; Human; Rats; S-Adenosylmethionine|ME; Tetrahydropteroylglutamate Methyltransferase|ME

Publication Type

JOURNAL ARTICLE; REVIEW; REVIEW, ACADEMIC

ISSN

0735-0414

Country of Publication

ENGLAND

CAS Registry/EC Number

EC 2.1.1.13 (Tetrahydropteroylglutamate Methyltransferase); 29908-03-0 (S-Adenosylmethionine); 64-17-5 (Alcohol, Ethyl); 7005-18-7 (Methionine)

Record 9 from database: MEDLINE
Return To The Top

Title

Slowed synthesis of DNA and methionine is a pathogenetic mechanism common to dementia in Down's syndrome, AIDS and Alzheimer's disease?

Author

Regland B; Gottfries CG

Address

Department of Geriatrics and Rehabilitation, Uddevalla Hospital, Rosenhäll, Sweden.

Source

Med Hypotheses, 1992 May, 38:1, 11-9

Abstract

This is a presentation of the hypothesis of a pathogenetic mechanism common to the dementia seen in Alzheimer's disease (AD), Down's Syndrome (DS) and the acquired immunodeficiency syndrome (AIDS). As there is experimental evidence of defective DNA repair capacity in AD and DS, unrepaired damage to DNA occurs in these diseases and may lead to complete breakdown of cellular function and ultimate cell death. Cobalamin and folate are coordinated in a vulnerable key position in the synthesis of DNA and S-adenosylmethionine (SAM). Cobalamin/folate deficiency, a significant feature in senile dementia of Alzheimer type and in AIDS-related dementia complex, will result in concomitant slowed synthesis of DNA and SAM. The enzyme cystathionine-beta-synthetase (CBS) has been localized to the chromosome band 21q22.3. Owing to gene dosage, CBS activity is increased in trisomy 21. As a consequence, cobalamin/folate metabolism is inhibited, which leads to slowing of DNA and SAM synthesis in DS patients. Amyloidosis is a hallmark of AD and DS brain neuropathology and recent experimental findings support the view that amyloid or amyloid precursors stimulate DNA synthesis, which is in agreement with the hypothesis presented in this paper. In summary, demented patients with cobalamin/folate deficiency, trisomy 21 and human immunodeficiency virus (HIV) infection display a simultaneous downregulation of DNA and SAM synthesis, which may indicate a pathway common to the dementia seen in AD, DS and AIDS.

Language of Publication

English

Unique Identifier

92310301

MeSH Heading (Major)

Alzheimer's Disease|PA/*PP; AIDS Dementia Complex|PA/*PP; Dementia|ET/PA/*PP; Down Syndrome|PA/*PP; DNA|*BI; Methionine|*BI

MeSH Heading

Amyloidosis|ET/PA/PP; Cell Death; DNA Repair; DNA Replication; Human; Models, Biological

Publication Type

JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

ISSN

0306-9877

Country of Publication

ENGLAND

CAS Registry/EC Number

7005-18-7 (Methionine); 9007-49-2 (DNA)

Record 10 from database: MEDLINE
Return To The Top

Title

Methionine deprivation regulates the translation of functionally-distinct c-Myc proteins.

Author

Hann SR

Address

Department of Cell Biology, Vanderbilt Univeristy, School of Medicine, Nashville, Tennessee 37232-2175, USA.

Source

Adv Exp Med Biol, 1995, 375:, 107-16

Abstract

Numerous studies have demonstrated a critical role for the c-myc gene in the control of cellular growth. Alterations of the c-myc gene have been found associated with many different types of tumors in several species, including humans. The increased synthesis of one of the major forms of c-Myc protein, c-Myc 1, upon methionine deprivation provides a link between the regulation of oncogenes and the nutritional status of the cell. While deregulation or overexpression of the other major form, c-Myc 2, has been shown to cause tumorigenesis, the synthesis of c-Myc 1 protein is lost in many tumors. This suggests that the c-Myc 1 protein is necessary to keep the c-Myc 2 protein "in check" and prevent certain cells from becoming tumorigenic. Indeed, we have shown that overproduction of c-Myc 1 can inhibit cell growth. We have also shown that c-Myc 1 and 2 proteins have a differential molecular function in the regulation of transcription through a new binding site of Myc/Max heterodimers. We have also recently identified new translational forms of the c-Myc protein which we term delta-c-Myc. These proteins arise from translational initiation at downstream start sites which yield N-terminally-truncated c-Myc proteins. Since these proteins lack a significant portion of the transactivation domain of c-Myc, they behave as dominant-negative inhibitors of the full-length c-Myc 1 and 2 proteins. The synthesis of delta-c-Myc proteins is also regulated during cell growth and is repressed by methionine deprivation. Therefore, the synthesis of c-Myc 1 and delta-c-Myc proteins are reciprocally regulated by methionine availability. We have also found some tumor cell lines which synthesize high levels of the delta-c-Myc proteins. Taken together, our data suggest that c-Myc function is dependent on the levels of these different translational forms of c-Myc protein which are regulated by the nutritional status of the cell during growth. Numerous reports have demonstrated a fundamental and diverse role for the myc gene in cellular events, including proliferation, differentiation and apoptosis (Cole 1986; Spencer and Groudine 1991; Askew et al. 1991; Evan et al. 1992). This is dramatically illustrated by the frequent occurrence of a variety of tumors in many species having alterations of myc genes and the transduction of c-myc sequences by retroviruses (Spencer and Groudine 1991).4+ Eisenman 1990).(ABSTRACT TRUNCATED AT 400 WORDS)

Language of Publication

English

Unique Identifier

95373361

MeSH Heading (Major)

Methionine|AD/*DF; Proto-Oncogene Proteins c-myc|*GE/PH; Translation, Genetic|*

MeSH Heading

Animal; Base Sequence; Gene Expression Regulation; Genes, myc; Human; Molecular Sequence Data; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.

Publication Type

JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

ISSN

0065-2598

Country of Publication

UNITED STATES

CAS Registry/EC Number

0 (Proto-Oncogene Proteins c-myc); 7005-18-7 (Methionine)

Record 11 from database: MEDLINE
Return To The Top

Title

S-adenosyl-L-methionine synthetase and methionine metabolism deficiencies in cirrhosis.

Author

Mato JM; Alvarez L; Ortiz P; Mingorance J; Durán C; Pajares MA

Address

Instituto de Investigaciones Biomédicas, CSIC, Madrid, Spain.

Source

Adv Exp Med Biol, 1994, 368:, 113-7

Abstract

Methionine metabolism impairment in human liver disease has been related with an alteration in SAM-synthetase. This deficiency is produced by a post-translational event since human liver cirrhosis presents normal levels of SAM-synthetase mRNA in spite of a more than 50% diminution in its activity. A series of different experiments on the structure and activity of this enzyme have provided strong evidence that SAM-synthetase is regulated by reduced/oxidized glutathione ratio. Restoration of glutathione levels by the addition of S-adenosyl-methionine or glutathione esters in various experimental conditions (buthionine sulfoximine and carbon tetrachloride intoxication) resulted in a normalization of the SAM-synthetase diminution caused by the toxics and an attenuation of the morfological alteration produced in the liver, including fiber production. This findings might have pharmacological implications in the treatment of liver diseases, since the possible beneficial effect of long term administration of SAM could include a reduction of fiber production.

Language of Publication

English

Unique Identifier

95259561

MeSH Heading (Major)

Liver Cirrhosis|DT/EN/*ME/PA; Methionine|*DF/ME; Methionine Adenosyltransferase|*DF

MeSH Heading

Animal; Human; Liver Cirrhosis, Experimental|DT/EN/ME/PA; Support, Non-U.S. Gov't

Publication Type

JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

ISSN

0065-2598

Country of Publication

UNITED STATES

CAS Registry/EC Number

EC 2.5.1.6 (Methionine Adenosyltransferase); 7005-18-7 (Methionine)

Record 12 from database: MEDLINE
Return To The Top

Title

Oxidation of methionyl residues in proteins: tools, targets, and reversal.

Author

Vogt W

Address

Max Planck Institut für experimentelle Medizin, Göttingen, Germany.

Source

Free Radic Biol Med, 1995 Jan, 18:1, 93-105

Abstract

Methionine (Met) is one of the most readily oxidized amino acid constituents of proteins. It is attacked by H2O2, hydroxyl radicals, hypochlorite, chloramines, and peroxynitrite, all these oxidants being produced in biological systems. The oxidation product, Met sulfoxide, can be reduced back to Met by Met sulfoxide reductase. Numerous proteins lose functional activity by Met oxidation. However, functional activation of proteins by Met oxidation has also been observed. Functional changes by Met oxidation in a given protein appear to have pathophysiological significance in some cases. Considering the reversibility of Met oxidation and the functional changes associated with the oxidation, it seems possible that Met oxidation/reduction in proteins may be one means to control homeostasis in biological systems.

Language of Publication

English

Unique Identifier

95203764

MeSH Heading (Major)

Methionine|AA/*CH/ME; Proteins|*CH

MeSH Heading

alpha 1-Antitrypsin|CH; Complement 5|CH; Free Radicals; Hormones|CH; Human; Oxidation-Reduction; Oxidoreductases|ME

Publication Type

JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

ISSN

0891-5849

Country of Publication

UNITED STATES

CAS Registry/EC Number

EC 1. (Oxidoreductases); EC 1.- (methionine sulfoxide reductase); 0 (alpha 1-Antitrypsin); 0 (Complement 5); 0 (Free Radicals); 0 (Hormones); 0 (Proteins); 454-41-1 (methionine sulfoxide); 7005-18-7 (Methionine)

Record 13 from database: MEDLINE
Return To The Top

Title

Methyl donors in the diet and responses to chemical carcinogens.

Author

Rogers AE

Address

Boston University School of Medicine, Department of Pathology and Laboratory Medicine, Mallory Institute of Pathology, MA 02118.

Source

Am J Clin Nutr, 1995 Mar, 61:3 Suppl, 659S-665S

Abstract

Dietary deficiency of labile methyl donors (choline and methionine) increases spontaneous and chemically induced hepatocarcinogenesis in rats. Chemical carcinogenesis in the colon, mammary gland, esophagus, and pancreas also may be increased. The mechanism of the dietary effect is not known but may be related to reduced methylation of DNA and RNA, hyperplasia of target cells, increased peroxidative damage, and altered carcinogen or promoter metabolism. Folate deficiency also is associated with increased carcinogenesis, an effect that may be mediated through participation in methyl metabolism; this has been less extensively studied. Deficiency of these three nutrients also may play a role in the elevated cancer risk in humans that is associated with ethanol intake.

Language of Publication

English

Unique Identifier

95185441

MeSH Heading (Major)

Carcinogens|*TO; Choline Deficiency|*CO; Folic Acid Deficiency|*CO; Methionine|*DF; Neoplasms|*ET

MeSH Heading

Animal; Diet; Human; Liver Neoplasms, Experimental|ET; Methylation

Publication Type

JOURNAL ARTICLE; REVIEW; REVIEW, ACADEMIC

ISSN

0002-9165

Country of Publication

UNITED STATES

CAS Registry/EC Number

0 (Carcinogens); 7005-18-7 (Methionine)

Record 14 from database: MEDLINE
Return To The Top

Title

Mechanisms and consequences of the impaired trans-sulphuration pathway in liver disease: Part II. Clinical consequences and potential for pharmacological intervention in cirrhosis.

Author

Pisi E; Marchesini G

Address

Istituto di Clinica Medica Generale e Terapia Medica, Università di Bologna, Italy.

Source

Drugs, 1990, 40 Suppl 3:, 65-72

Abstract

The liver is actively involved in the metabolism of the sulphur-containing essential amino acid, methionine. Methionine is transformed into S-adenosyl-L-methionine (SAMe) and then into sulphur-containing metabolites (cysteine, taurine and glutathione) via the trans-sulphuration pathway. Liver disease may affect the trans-sulphuration pathway and decrease the clearance of methionine, which leads to increased fasting methionine concentrations in blood and reduced formation of cysteine and glutathione. There is evidence that this defect, located at the level of SAMe-synthetase, may cause nutritional defects and contribute to negative nitrogen balance whenever non-essential sulphur-containing amino acids are not supplied in adequate amounts. In addition, cirrhotic patients may be at increased risk of hepatotoxicity after treatment with substances which are detoxified via glutathione. The SAMe-synthetase block may be overcome by administration of oral or intravenous SAMe, which improves the fasting amino acid profile and increases the hepatic glutathione concentration. Controlled studies on long term SAMe treatment in patients with cirrhosis are needed to confirm this possible beneficial effect.

Language of Publication

English

Unique Identifier

91184034

MeSH Heading (Major)

Liver Cirrhosis|DT/*ME; Methionine|*ME/PK

MeSH Heading

Amino Acids|BL; Human; S-Adenosylmethionine|TU

Publication Type

JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

ISSN

0012-6667

Country of Publication

UNITED STATES

CAS Registry/EC Number

0 (Amino Acids); 29908-03-0 (S-Adenosylmethionine); 7005-18-7 (Methionine)

Record 15 from database: MEDLINE
Return To The Top

Title

Mechanisms and consequences of the impaired trans-sulphuration pathway in liver disease: Part I. Biochemical implications.

Author

Mato JM; Corrales F; Martin-Duce A; Ortiz P; Pajares MA; Cabrero C

Address

Departamento de Metabolismo, Nutrición y Hormonas, Fundación Jiménez Diaz, Madrid, Spain.

Source

Drugs, 1990, 40 Suppl 3:, 58-64

Abstract

The energy-dependent conversion of methionine to S-adenosyl-L-methionine (SAMe) is catalysed by S-adenosyl-L-methionine synthetase (SAMe-synthetase) in the liver. In the hepatocyte, an equilibrium exists between the high and low molecular weight forms of SAMe-synthetase, which consist of a tetramer and a dimer, respectively, of a 48.5 kilodalton subunit. The 2 enzymic forms differ in their affinity for methionine and sensitivity to inhibition by pyrophosphate; 2 of the sulfhydryl groups of SAMe-synthetase have been identified as essential for the normal functioning of the enzyme. In patients with liver cirrhosis, a marked reduction in the utilisation of the high molecular weight SAMe-synthetase and displacement of the equilibrium occur, the molecular mechanism of which has yet to be established. This loss of activity is associated with a delay in methionine clearance and impairment of the trans-sulphuration pathway, which normally eliminates excess methionine by oxidising homocysteine to sulphate anion. It is hypothesised that in normal liver function the essential sulfhydryl groups of SAMe-synthetase are protected from oxidation by glutathione, a by-product of the trans-sulphuration pathway. However, glutathione levels are reduced in liver cirrhosis, and this may result in increased oxidation of the essential sulfhydryl groups, and consequent inactivation of the enzyme. Thus, the trans-sulphuration pathway may play an important role in the maintenance of normal SAMe-synthetase activity.

Language of Publication

English

Unique Identifier

91184033

MeSH Heading (Major)

Liver|*ME/PH; Liver Diseases|*ME; Methionine|*ME; Methionine Adenosyltransferase|*BI/ME; S-Adenosylmethionine|*ME

MeSH Heading

Human; Support, Non-U.S. Gov't

Publication Type

JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

ISSN

0012-6667

Country of Publication

UNITED STATES

CAS Registry/EC Number

EC 2.5.1.6 (Methionine Adenosyltransferase); 29908-03-0 (S-Adenosylmethionine); 7005-18-7 (Methionine)

Record 16 from database: MEDLINE
Return To The Top

Title

Chemoattractant receptor affinity reflects its ability to transduce different biological responses.

Author

Snyderman R

Source

Agents Actions Suppl, 1983, 12:, 323-36

Abstract

The oligopeptide chemotactic factor receptor in human PMN membranes exists in two affinity states which are in part interconvertible and regulated by guanine nucleotides. In whole cells, only one affinity of the receptor can be seen, presumably due to the high intracellular levels of guanine nucleotides as well as rapidly ongoing cellular processes which allow the detection of only a single affinity state. There is strong evidence to suggest that the affinity of the chemoattractant receptor in whole PMNs can be modified by agents which alter the physical state of the PMN membrane. The average affinity of the oligopeptide chemotactic factor receptor can be enhanced by aliphatic alcohols which decrease membrane microviscosity. Under these conditions, chemotactic responsiveness of PMNs is enhanced but 0(2-) production and secretion initiated by chemoattractants is markedly depressed. When the affinity of the receptor is lowered as in the case of amphotericin B, chemotaxis is depressed but lysozyme secretion is enhanced. These data indicate that the transduction mechanisms for certain biological responses initiated by the chemoattractant receptor are heterogeneous. It can be hypothesized that the particular transduction pathway initiated by chemoattractant receptor occupancy is reflected by the affinity state of the receptor. The higher affinity state initiates chemotactic signals whereas the lower affinity state initiates 0(2-) production and secretion. By altering the affinity of the receptor using pharmacological means one may be able to modify the biological activity of human PMNs.

Language of Publication

English

Unique Identifier

83175104

MeSH Heading (Major)

Methionine|*AA; N-Formylmethionine|*AA/ME; Neutrophils|*ME; Oligopeptides|*ME; Receptors, Cell Surface|DE/*ME

MeSH Heading

Alcohols|PD; Amphotericin B|PD; Animal; Comparative Study; Guanine Nucleotides|PD; Human; In Vitro; Kinetics; Lysosomes|DE/EN; Membrane Fluidity|DE

Publication Type

JOURNAL ARTICLE; REVIEW

ISSN

0379-0363

Country of Publication

SWITZERLAND

CAS Registry/EC Number

0 (chemotactic peptide receptor); 0 (Alcohols); 0 (Guanine Nucleotides); 0 (Oligopeptides); 0 (Receptors, Cell Surface); 1397-89-3 (Amphotericin B); 4289-98-9 (N-Formylmethionine); 59880-97-6 (N-Formylmethionine Leucyl-Phenylalanine); 7005-18-7 (Methionine)

Record 17 from database: MEDLINE
Return To The Top

Title

Dynamics of human neutrophil receptors for the chemoattractant fmet-leu-phe.

Author

Gallin JI; Seligmann BE; Fletcher MP

Source

Agents Actions Suppl, 1983, 12:, 290-308

Abstract

Neutrophils contain an intracellular pool of binding sites for the chemoattractant fmet-leu-phe with the same density as specific granules. This pool of receptors appears to be translocated to the plasma membrane during degranulation and may be important for receptor renewal during chemotaxis. Scatchard analyses of fmet-leu-phe binding to neutrophils and isolated plasma membranes are nonlinear and calculated Hill coefficients of binding to these fractions were about 0.67, suggesting negative cooperativity and/or heterogeneity of receptors. Some of the features of the nonlinear Scatchard curves may reflect heterogeneity of binding among cells since binding of fmet-leu-phe-lys-fluorescein to cells is heterogeneous when simultaneously monitored in the fluorescence activated cell sorter with a fluorescent probe of membrane potential. Following addition of a chemoattractant cells showing a depolarization have more chemoattractant associated with them than cells showing no change of membrane potential or a hyperpolarization. The cell associated chemoattractant is largely in a displaceable pool on the cells showing depolarization while it is in a nondisplaceable pool in the cells that either do not respond or show a hyperpolarization. Studies of the adaptation of human neutrophils responsiveness to fmet-leu-phe elicited membrane potential changes indicate that fmet-leu-phe stimulated decreases in receptor affinity accompany such adaptation. This decreased affinity appears to involve heterogeneity and/or negative cooperative interaction of receptors. The dynamics of chemoattractant receptors that have been reviewed provide further insights for studying the concepts behind the spatial and temporal mechanisms by which cells respond and adapt to a gradient of chemoattractant.

Language of Publication

English

Unique Identifier

83175102

MeSH Heading (Major)

Methionine|*AA; N-Formylmethionine|*AA/ME; Neutrophils|*PH; Oligopeptides|*ME; Receptors, Cell Surface|*ME

MeSH Heading

Adaptation, Physiological; Cell Membrane|PH; Chemotaxis, Leukocyte; Comparative Study; Cytoplasmic Granules|PH; Fluorescent Dyes; Human; In Vitro; Kinetics

Publication Type

JOURNAL ARTICLE; REVIEW

ISSN

0379-0363

Country of Publication

SWITZERLAND

CAS Registry/EC Number

0 (chemotactic peptide receptor); 0 (Fluorescent Dyes); 0 (Oligopeptides); 0 (Receptors, Cell Surface); 4289-98-9 (N-Formylmethionine); 59880-97-6 (N-Formylmethionine Leucyl-Phenylalanine); 7005-18-7 (Methionine)

Record 18 from database: MEDLINE
Return To The Top

Title

Biochemistry of sulfur-containing amino acids.

Author

Cooper AJ

Source

Annu Rev Biochem, 1983, 52:, 187-222

Abstract

The literature on sulfur amino acid metabolism is too vast for a short chapter to cover in great depth. I attempt here a brief overview with references to many specialized review articles. This review emphasizes aspects of sulfur amino acid metabolism elucidated in the last ten years, in particular aspects not generally covered in biochemistry texts, e.g. transaminative pathways of methionine metabolism. A selected list of reviews is given in references 1-15. References to reviews on glutathione are covered in the chapter by A. Meister in this volume (1a).

Language of Publication

English

Unique Identifier

83307233

MeSH Heading (Major)

Cysteine|*ME; Homocysteine|*ME; Methionine|AA/*ME; S-Adenosylmethionine|*ME

MeSH Heading

Adenosine|AA/ME; Amino Acid Metabolism, Inborn Errors|ME; Animal; Human; Oxidoreductases|ME; Structure-Activity Relationship; Sulfur|ME; Sulfurtransferases|ME; Support, U.S. Gov't, P.H.S.; Thionucleosides|ME; Thiosulfate Sulfurtransferase|ME

Publication Type

JOURNAL ARTICLE; REVIEW

ISSN

0066-4154

Country of Publication

UNITED STATES

CAS Registry/EC Number

EC 1. (Oxidoreductases); EC 1.8.- (thiosulfate reductase); EC 2.8.1 (Sulfurtransferases); EC 2.8.1.1 (Thiosulfate Sulfurtransferase); EC 2.8.1.2 (3-mercaptopyruvate sulphurtransferase); 0 (Thionucleosides); 2457-80-9 (5'-methylthioadenosine); 29908-03-0 (S-Adenosylmethionine); 4371-52-2 (Cysteine); 454-28-4 (Homocysteine); 58-61-7 (Adenosine); 583-92-6 (2-keto-4-methylthiobutyric acid); 7005-18-7 (Methionine); 7704-34-9 (Sulfur)

Record 19 from database: MEDLINE
Return To The Top

Title

Diseases of sulphur metabolism: implications for the methionine-homocysteine cycle, and vitamin responsiveness.

Author

Mudd SH

Source

Ciba Found Symp, 1979, :72, 239-58

Abstract

Sixteen inherited human diseases are now recognized, affecting most of the major steps in sulphur metabolism. Studies of patients with three types of homocystinuria have demonstrated unequivocally the major role of cystathionine formation in degradation of homocysteine, and the importance of homocysteine remethylation. Methionine balance studies of normal subjects and of a sarcosine oxidase-deficient subject have shown the predominant role of creatine synthesis in methionine utilization and permitted assessment of the rate of oxidation of the methyl group of methionine. Together, the results demonstrate that once regulatory adjustments have been made the rate of methylneogensis is nicely controlled so that labile methyl groups are made available in amounts just sufficient to meet the needs for methionine. When excess methionine is ingested the four-carbon moiety is diverted into cystathionine, the methyl group is oxidized via sarcosine and the flow of partially oxidized one-carbon units is diverted away from 5-methyltetrahydrofolate toward CO2. Studies of cystathionine synthase-deficient patients demonstrate that the capacity to respond or not to respond to pyridoxine administration is genetically controlled, probably through structural differences in mutant cystathionine synthases. However, the properties of the enzyme crucial in conferring responsiveness have not yet been identified.

Language of Publication

English

Unique Identifier

80245604

MeSH Heading (Major)

Homocysteine|*ME/PH; Metabolism, Inborn Errors|*ME; Methionine|*ME; Pyridoxine|*TU; Sulfur|*ME

MeSH Heading

Adolescence; Cystathionine beta-Synthase|ME; Homocystinuria|DT/EN/GE; Human; Methylation

Publication Type

JOURNAL ARTICLE; REVIEW

ISSN

0300-5208

Country of Publication

NETHERLANDS

CAS Registry/EC Number

EC 4.2.1.22 (Cystathionine beta-Synthase); 454-28-4 (Homocysteine); 65-23-6 (Pyridoxine); 7005-18-7 (Methionine); 7704-34-9 (Sulfur)

Record 20 from database: MEDLINE
Return To The Top

Title

Transmethylation hypothesis of schizophrenia: methionine and nicotinic acid.

Author

Nestoros JN; Ban TA; Lehmann HE

Source

Int Pharmacopsychiatry, 1977, 12:4, 215-46

Abstract

The transmethylation hypothesis of schizophrenia was reviewed with considerations that large doses of methionine when combined with a monoamine oxidase inhibitor lead to exacerbation of psychotic symptoms in a significant percentage of chronic schizophrenic patients. It was noted that nicotinic acid in the dosage of 3,000 mg/day can neither prevent nor counteract the psychopathology thus induced.

Language of Publication

English

Unique Identifier

78066284

MeSH Heading (Major)

Methionine|AD/AE/*ME; Nicotinic Acids|*AD; Schizophrenia|ET/*ME

MeSH Heading

Catechol Methyltransferase|ME; Female; Human; Male; Methylation; Methyltransferases|ME; Monoamine Oxidase Inhibitors|AD

Publication Type

JOURNAL ARTICLE; REVIEW

ISSN

0020-8272

Country of Publication

SWITZERLAND

 

---

Record 21 from database: MEDLINE
Return To The Top

Title

Effects on transmethylation by high-dose 6-mercaptopurine and methotrexate infusions during consolidation treatment of acute lymphoblastic leukemia.

Author

Keuzenkamp-Jansen CW; De Abreu RA; Blom HJ; Bökkerink JP; Trijbels JM

Address

Laboratory of Pediatrics, University Hospital St. Radboud, Nijmegen, The Netherlands.

Source

Biochem Pharmacol, 1996 May 3, 51:9, 1165-71

Abstract

6-mercaptopurine (6MP) cytotoxicity is caused by thioguanine and methylthioinosine nucleotides. Thiopurine methylation occurs to a large extent in vivo and in vitro. In this reaction, S-adenosyl-L-methionine (AdoMet), produced from

and ATP, is converted into S-adenosyl-L-homocysteine (AdoHcy) which, in turn, is hydrolyzed into homocysteine. Remethylation of homocysteine into methionine is inhibited by methotrexate (MTX). In cultured lymphoblasts, AdoMet: AdoHcy ratio and DNA methylation decrease after incubation with 6MP. The aim of the present study was to investigate the influence of high-dose 6MP on the methylation capacity in children with acute lymphoblastic leukemia. Five patients received 4 courses with high-dose intravenous MTX (5' g.m-2 in 24 hr) immediately followed by high-dose 6MP (1300 mg.m-2 in 24 hr). Five control patients received high-dose MTX and oral 6MP (25 mg.m -2 daily for 8 weeks). Leucovorin rescue was started at 36 hr in both groups. In the intravenous 6MP group, 6-methylmercaptopurine, its riboside, and 6-methylmercapto-8-hydroxypurine were detectable in plasma in concentrations of 0.3-2.6 muM (6MP steady state levels: 11.6 muM). In red blood cells, mean methylthioinosine nucleotide levels were one third of those of ATP (13.1 nmol/10(8)). AdoHcy levels (10 pmol/10(8)) remained constant in both groups and AdoMet was not detectable ( < 20 pmol/10(8)). In both groups, plasma homocysteine increased and

decreased following administration of MTX. The delay in the recovery of methionine in the intravenous 6MP group after MTX infusion is probably the result of an increased demand on methyl groups during 6MP infusion.

Language of Publication

English

Unique Identifier

96221547

MeSH Heading (Major)

Antimetabolites, Antineoplastic|AD/PK/*TU; Antineoplastic Agents, Combined|AD/*TU; Leukemia, Lymphocytic, Acute, L1|*DT

MeSH Heading

Child; Erythrocytes|ME; Homocysteine|BL; Human; Methionine|BL; Methotrexate|AD/PK; Methylation; Purine Nucleotides|BL; S-Adenosylhomocysteine|BL; S-Adenosylmethionine|BL; Support, Non-U.S. Gov't; 6-Mercaptopurine|AD/PK

Publication Type

JOURNAL ARTICLE

ISSN

0006-2952

Country of Publication

ENGLAND

CAS Registry/EC Number

0 (Antimetabolites, Antineoplastic); 0 (Antineoplastic Agents, Combined); 0 (Purine Nucleotides); 29908-03-0 (S-Adenosylmethionine); 454-28-4 (Homocysteine); 50-44-2 (6-Mercaptopurine); 59-05-2 (Methotrexate); 7005-18-7 (Methionine); 979-92-0 (S-Adenosylhomocysteine)

Record 22 from database: MEDLINE
Return To The Top

Title

Isolation of the murine S100 protein MRP14 (14 kDa migration-inhibitory-factor-related protein) from activated spleen cells: characterization of post-translational modifications and zinc binding.

Author

Raftery MJ; Harrison CA; Alewood P; Jones A; Geczy CL

Address

Immunology Group, Heart Research Institute, Camperdown, New South Wales, Australia.

Source

Biochem J, 1996 May 15, 316 ( Pt 1):, 285-93

Abstract

MRP14 (macrophage migration-inhibitory factor-related protein of molecular mass 14 kDa) is an S100 calcium binding protein constitutively expressed in human neutrophils which may be associated with cellular activation/inflammation. Murine MRP14 expression was up-regulated following concanavalin A activation of spleen cells, and the protein was isolated from conditioned medium in high yield (approx. 500 ng/ml). MRP14 had a mass of 12972 +/- 2 Da by electrospray ionization MS, whereas the theoretical mass derived from the cDNA sequence, after removal of the initiator Met, was 12918 Da, suggesting that the protein was post-translationally modified. We identified four post-translational modifications of MRP14: removal of the N-terminal Met, N-terminal acetylation, disulphide bond formation between Cys79 and Cys90, and 1-methylation of His106; the calculated mass was then 12971.8 Da. Methylation of His106 was further characterized after incubation of spleen cells with L-[methyl-3H]Met during concanavalin A stimulation. Sequential analysis of a peptide (obtained by digestion with Lys C) containing methylated His indicated that > 80% of the label in the cycle corresponded to His106, suggesting that the methyl residue was transferred from S-adenosyl-L-methionine. Comparison of the C18 reverse-phase HPLC retention times of phenylthiocarbamoyl derivatives of a hydrolysed digest peptide of MRP14 with those of standards confirmed methyl substitution on the 1-position of the imidazole ring. MRP14 bound more 85Zn2+ than the same amounts of the 10 kDa chemotactic protein (CP10) or S100 beta. Ca2+ decreased Zn2+ binding in S100 beta but it did not influence binding to MRP14, suggesting that the Zn2+ binding site was distinct from and independent of the two Ca2+ binding domains.

Language of Publication

English

Unique Identifier

96235204

MeSH Heading (Major)

Antigens, Differentiation|CH/*IP/*ME; Calcium-Binding Proteins|CH/*IP/*ME; Gene Expression Regulation|*DE; Lymphocytes|DE/*ME; Protein Processing, Post-Translational|*; Spleen|IM/*ME; Zinc|*ME/PD

MeSH Heading

Acetylation; Amino Acid Sequence; Animal; Cells, Cultured; Chromatography, High Pressure Liquid; Comparative Study; Concanavalin A|PD; Cysteine; Disulfides|AN; Histidine; Human; Lymphocyte Transformation; Methionine|ME; Methylation; Mice; Molecular Sequence Data; Neutrophils|ME; Peptide Fragments|CH/IP; Sequence Homology, Amino Acid; Spectrum Analysis, Mass; Support, Non-U.S. Gov't

Publication Type

JOURNAL ARTICLE

ISSN

0264-6021

Country of Publication

ENGLAND

CAS Registry/EC Number

0 (Antigens, Differentiation); 0 (Calcium-Binding Proteins); 0 (Disulfides); 0 (MRP-14 protein); 0 (Peptide Fragments); 11028-71-0 (Concanavalin A); 4371-52-2 (Cysteine); 7005-18-7 (Methionine); 7006-35-1 (Histidine); 7440-66-6 (Zinc)

Record 23 from database: MEDLINE
Return To The Top

Title

Effect of methionine loading on 5-methyltetrahydrofolate, S-adenosylmethionine and S-adenosylhomocysteine in plasma of healthy humans.

Author

Loehrer FM; Haefeli WE; Angst CP; Browne G; Frick G; Fowler B

Address

Metabolic Unit, University Children's Hospital Basel, Switzerland.

Source

Clin Sci (Colch), 1996 Jul, 91:1, 79-86

Abstract

1. Elevated plasma homocysteine concentration, either in the fasting state or after methionine loading, is an independent risk factor for vascular disease in man. Methionine loading has been used to investigate impaired methionine metabolism, especially of the trans-sulphuration pathway, but most studies have focused on changes in homocysteine. 2. We investigated the effect of methionine excess on total plasma homocysteine, 5-methyltetrahydrofolate (which is the active form of folate in the remethylation of homocysteine to methionine), S-adenosyl-methionine (the first metabolite of methionine) and S-adenosylmethionine) (the demethylated product of S-adenosylmethionine) over 24h in 12 healthy subjects. 3. As well as the expected increase in homocysteine (from 8.0 +/- 1.3 to 32.6 +/- 10.3 mumol/l, mean +/- SD, P < 0.001), S-adenosylmethionine showed a significant transient increase (from 37.9 +/- 25.0 to 240.3 +/- 109.2 nmol/l, P < 0.001), which correlated well with homocysteine (r2 = 0.92, P < 0.001). 5-Methyltetrahydrofolate values decreased significantly (from 23.2 +/- 7.2 to 13.1 +/- 2.9 nmol/l, P < 0.01), and gradually returned to baseline levels after 24h. No significant change over the time of measurement was found for S-adenosylhomocysteine. 4. The sequence of metabolic changes observed in this study strongly suggests that a change in either homocysteine or S-adenosylmethionine may cause a reduction in 5-methyltetrahydrofolate. This must be considered in evaluating the relationship between folate and homocysteine in vascular disease. The metabolic relationships illustrated in this study should be evaluated in the search for pathogenetic mechanisms of mild hyperhomocysteinaemia and vascular disease.

Language of Publication

English

Unique Identifier

96370368

MeSH Heading (Major)

Methionine|*ME; S-Adenosylhomocysteine|*BL; S-Adenosylmethionine|*BL; Tetrahydrofolates|*BL

MeSH Heading

Adult; Chromatography, High Pressure Liquid; Female; Homocysteine|BL; Human; Kinetics; Male; Middle Age; Support, Non-U.S. Gov't

Publication Type

JOURNAL ARTICLE

ISSN

0143-5221

Country of Publication

ENGLAND

CAS Registry/EC Number

0 (Tetrahydrofolates); 134-35-0 (5-methyltetrahydrofolate); 29908-03-0 (S-Adenosylmethionine); 454-28-4 (Homocysteine); 7005-18-7 (Methionine); 979-92-0 (S-Adenosylhomocysteine)

Record 24 from database: MEDLINE
Return To The Top

Title

DNA hypomethylation and proliferative activity are increased in the rectal mucosa of patients with long-standing ulcerative colitis.

Author

Glória L; Cravo M; Pinto A; de Sousa LS; Chaves P; Leitão CN; Quina M; Mira FC; Soares J

Address

Servico de Gastrenterologia, Instituto Português de Oncologia Francisco Gentil de Lisboa, Portugal.

Source

Cancer, 1996 Dec 1, 78:11, 2300-6

Abstract

BACKGROUND: DNA methylation and DNA cytometric parameters were evaluated in the rectal mucosa from patients with extensive and long-standing ulcerative colitis. METHODS: Twenty-six patients with extensive disease for more than 7 years and 11 healthy controls were included. Global DNA methylation was assessed as the capacity of the DNA test to incorporate [3H]methyl groups from [3H]-S-adenosyl-methionine in the presence of Sss1 methylase. A higher incorporation reflects a lower state of intrinsic methylation. DNA ploidy, S-phase fraction, and proliferative index (PI = S + G2M) of the cell cycle were analyzed by flow cytometry. RESULTS: Incorporation of the [3H]methyl groups into DNA was 10-fold higher in patients compared with controls (P < 0.001) and was significantly higher in patients with histologically active disease (P = 0.02). With regard to flow cytometry, all samples showed a diploid pattern, but S-phase fraction and the proliferative index values were significantly increased in patients compared with controls (P = 0.0007 and P = 0.003, respectively). A positive correlation was found between S-phase fraction and proliferative index and the number of exacerbations of the disease (P < 0.005), and there was a trend among those patients who had disease for longer than 20 years to present with increased cellular proliferation compared with those with a shorter evolution of disease (P > 0.05). CONCLUSIONS: DNA hypomethylation and proliferative activity are increased in this group of patients, supporting the concept that their colonic mucosa undergoes epigenetic and kinetic changes that might predispose these individuals to develop colorectal neoplasms. However, it cannot be ruled out that these markers solely reflect hyperproliferation associated with active inflammation.

Language of Publication

English

Unique Identifier

97095974

MeSH Heading (Major)

Colitis, Ulcerative|*ME/*PA; DNA Methylation|*

MeSH Heading

Adult; Aged; Cell Division; Female; Flow Cytometry; Human; Intestinal Mucosa|ME/PA; Male; Middle Age; Ploidies; S Phase|GE

Publication Type

JOURNAL ARTICLE

ISSN

0008-543X

Country of Publication

UNITED STATES

Record 25 from database: MEDLINE
Return To The Top

Title

In vitro effects of methotrexate on polyamine levels in lymphocytes from rheumatoid arthritis patients.

Author

Nesher G; Osborn TG; Moore TL

Address

Department of Internal Medicine, Saint Louis University Health Sciences Center, Missouri 63104, USA.

Source

Clin Exp Rheumatol, 1996 Jul-Aug, 14:4, 395-9

Abstract

OBJECTIVE: Several studies have documented increased levels of polyamines in rheumatoid arthritis (RA). We have suggested that one of the mechanisms of action of methotrexate (MTX) involves the inhibition of polyamine synthesis in lymphocytes. In this study, we sought to establish the inhibitory effect of MTX on polyamine synthesis and its specificity. METHODS: Polyamine levels were determined in stimulated RA lymphocytes incubated in vitro with MTX and compared to levels in lymphocytes incubated with hydrocortisone, D-penicillamine, or medium alone. Lymphocyte polyamine levels were correlated with IgM-rheumatoid factor (RF) synthesis. RESULTS: Incubation with MTX resulted in concentration-dependent decreased intracellular levels of spermidine and spermine, while putrescine levels were not affected. Addition of folinic acid or S-adenosyl-methionine (SAM) prevented this MTX-induced inhibition. Incubation with D-penicillamine or hydrocortisone had no significant effect on polyamine levels. There was a positive correlation between intracellular polyamine levels and the inhibition of IgM-RF synthesis by MTX. CONCLUSION: These data suggest that MTX inhibits the synthesis of spermidine and spermine in stimulated RA lymphocytes through inhibition of the SAM-dependent pathway. This inhibition may be related to the immune-modulating properties of MTX.

Language of Publication

English

Unique Identifier

97025659

MeSH Heading (Major)

Antirheumatic Agents|*PD; Arthritis, Rheumatoid|*BL/DT/IM; Lymphocytes|DE/*ME; Methotrexate|*PD; Polyamines|AI/*ME

MeSH Heading

Anti-Inflammatory Agents, Steroidal|PD; Cell Culture; Chromatography, High Pressure Liquid; Comparative Study; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Human; Hydrocortisone|PD; IgM|IM; Penicillamine|PD; Putrescine|ME; Rheumatoid Factor|BI/DE; Spermidine|ME; Spermine|ME; Support, Non-U.S. Gov't

Publication Type

JOURNAL ARTICLE

ISSN

0392-856X

Country of Publication

ITALY

CAS Registry/EC Number

0 (Anti-Inflammatory Agents, Steroidal); 0 (Antirheumatic Agents); 0 (IgM); 0 (Polyamines); 110-60-1 (Putrescine); 124-20-9 (Spermidine); 50-23-7 (Hydrocortisone); 52-67-5 (Penicillamine); 59-05-2 (Methotrexate); 71-44-3 (Spermine); 9009-79-4 (Rheumatoid Factor)

Record 26 from database: MEDLINE
Return To The Top

Title

Effects of S-adenosyl-L-methionine on platelet thromboxane and vascular prostacyclin.

Author

De La Cruz JP; González-Correa JA; Martín-Aurioles E; Ortiz P; Sánchez de la Cuesta F

Address

Department of Pharmacology and Therapeutics, School of Medicine, University of Málaga, Spain.

Source

Biochem Pharmacol, 1997 Jun 1, 53:11, 1761-3

Abstract

We therefore designed the present study to evaluate the effect of S-adenosyl-L-methionine (SAMe) on the synthesis of platelet thromboxane and vascular prostacyclin. The experimental materials were human blood and aortic rings from untreated Wistar rats; and platelets and aortic rings from Wistar rats treated for 7 days with SAMe at 5 or 10 mg/kg/day s.c. The administration of 10 mg/Kg/day of SAMe to rats significantly increased vascular production of 6-keto-PGF1alpha. In vitro vascular production of 6-keto-PGF1alpha increased in a concentration-dependent manner when SAMe was incubated in the range of 10(-7) to 10(-4) M. The greatest increase was 167 +/- 15%, obtained in samples incubated with 5 x 10(-5) M SAMe. In aortic rings, lipid peroxidase production was inhibited in a concentration-dependent manner in the SAMe range of 10(-7) to 10(-5) M. Maximum inhibition (75.3 +/- 6.2%) was obtained with SAMe at 1.5 x 10(-5) M. Vascular 6-keto-PGF1alpha production showed a significant inverse linear correlation with vascular lipid peroxide production (Y = -0.04x + 18.1, r = 0.7309, P < 0.0001).

Language of Publication

English

Unique Identifier

97407582

MeSH Heading (Major)

Blood Platelets|*DE/ME; Epoprostenol|*BI; S-Adenosylmethionine|*PD; Thromboxane B2|*BI

MeSH Heading

Animal; Aorta|DE; Human; In Vitro; Lipid Peroxides|BI; Male; Rats; Rats, Wistar; Thiobarbituric Acid Reactive Substances|AN; 6-Ketoprostaglandin F1 alpha|BI

Publication Type

JOURNAL ARTICLE

ISSN

0006-2952

Country of Publication

ENGLAND

CAS Registry/EC Number

0 (Lipid Peroxides); 0 (Thiobarbituric Acid Reactive Substances); 29908-03-0 (S-Adenosylmethionine); 35121-78-9 (Epoprostenol); 54397-85-2 (Thromboxane B2); 58962-34-8 (6-Ketoprostaglandin F1 alpha)

Record 27 from database: MEDLINE
Return To The Top

Title

Double-blind, placebo-controlled cross-over study of intravenous S-adenosyl-L-methionine in patients with fibromyalgia.

Author

Volkmann H; N‡rregaard J; Jacobsen S; Danneskiold-Sams‡e B; Knoke G; Nehrdich D

Address

Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark.

Source

Scand J Rheumatol, 1997, 26:3, 206-11

Abstract

The objective of this study was to test the efficacy of intravenously administered S-adenosyl-L-methionine (SAMe) in patients with fibromyalgia (FM). Thirty-four out-patients with fibromyalgia symptoms received SAMe 600 mg i.v. or placebo daily for 10 days in a cross-over trial. There was no significant difference in improvement in the primary outcome: tender point change between the two treatment groups. There was a tendency towards statistical significance in favour of SAMe on subjective perception of pain at rest (p = 0.08), pain on movement (p = 0.11), and overall well-being (p = 0.17) and slight improvement only on fatigue, quality of sleep, morning stiffness, and on the Fibromyalgia Impact Questionnaire for pain. No effect could be observed on isokinetic muscle strength, Zerrsen self-assessment questionnaire, and the face scale. No effect of SAMe in patients with FM was found in this short term study.

Language of Publication

English

Unique Identifier

97369388

MeSH Heading (Major)

Fibromyalgia|*DT/PP; S-Adenosylmethionine|AD/*TU

MeSH Heading

Adult; Aged; Cross-Over Studies; Double-Blind Method; Female; Human; Injections, Intravenous; Male; Middle Age; Pain|DT/PP; Pain Measurement; Questionnaires; Severity of Illness Index; Support, Non-U.S. Gov't; Treatment Outcome

Publication Type

CLINICAL TRIAL; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL

ISSN

0300-9742

Country of Publication

NORWAY

CAS Registry/EC Number

29908-03-0 (S-Adenosylmethionine)

Record 28 from database: MEDLINE
Return To The Top

Title

Rapidity of onset of the antidepressant effect of parenteral S-adenosyl-L-methionine.

Author

Fava M; Giannelli A; Rapisarda V; Patralia A; Guaraldi GP

Address

Depression Research Program, Massachusetts General Hospital, Boston 02114, USA.

Source

Psychiatry Res, 1995 Apr 28, 56:3, 295-7

Abstract

A possible method of reducing the delay in antidepressant response is to use S-adenosyl-L-methionine (SAMe), a naturally occurring compound that appears to have a rapid onset of effect in the treatment of depression. In this open, multicenter study, 195 patients were given 400 mg of SAMe, administered parenterally, for 15 days. Depressive symptoms remitted after both 7 and 15 days of treatment with SAMe, and no serious adverse events were reported. Further studies with a double-blind design are needed to confirm this preliminary indication that SAMe is a relatively safe and fast-acting antidepressant.

Language of Publication

English

Unique Identifier

96055438

MeSH Heading (Major)

Antidepressive Agents|*TU; Depressive Disorder|*DT/PX; S-Adenosylmethionine|*TU

MeSH Heading

Adolescence; Adult; Aged; Human; Infusions, Parenteral; Middle Age; Psychiatric Status Rating Scales; Support, Non-U.S. Gov't; Time Factors

Publication Type

CLINICAL TRIAL; JOURNAL ARTICLE; MULTICENTER STUDY

ISSN

0165-1781

Country of Publication

IRELAND

CAS Registry/EC Number

0 (Antidepressive Agents); 29908-03-0 (S-Adenosylmethionine)

Record 29 from database: MEDLINE
Return To The Top

Title

Mouse liver nicotinamide N-methyltransferase pharmacogenetics: biochemical properties and variation in activity among inbred strains.

Author

Scheller T; Orgacka H; Szumlanski CL; Weinshilboum RM

Address

Department of Pharmacology, Mayo Medical School/Mayo Clinic/Mayo Foundation, Rochester, MN 55905, USA.

Source

Pharmacogenetics, 1996 Feb, 6:1, 43-53

Abstract

Nicotinamide N-methyltransferase (NNMT) catalyses the N-methylation of nicotinamide and other pyridines. Human liver NNMT activity shows large individual variations and a bimodal frequency distribution, raising the possibility that this activity, like those of many other methyltransferase enzymes, might be regulated by a genetic polymorphism. In an attempt to develop an experimental animal model for pharmacogenetic studies of NNMT, we determined optimal conditions for the measurement of hepatic NNMT activity in C57BL/6J mice. Mouse liver NNMT was a cytoplasmic enzyme with a pH optimum of 7.4 and apparent Km values for nicotinamide and S-adenosyl-L-methionine, cosubstrates for the reaction, of 370 and 6.5 microM, respectively. These properties were very similar to those of human liver NNMT, as was the relative sensitivity of the mouse liver enzyme to a series of methyltransferase inhibitors. Hepatic NNMT activity was then measured in tissue from male mice of 10 inbred strains. Average levels of NNMT activity in these strains varied by up to 14-fold and ranged from 1.13 +/- 0.18 U per mg protein (mean +/- SEM, n = 6) for C3H/HeJ mice to 16.0 +/- 1.16 U per mg protein in C57BR/cdJ animals. Average hepatic NNMT activities in female mice of six strains in which both sexes were studied varied from five-fold higher than those in males for "low activity' strains, to not significantly different for "high activity' strains. A series of properties of NNMT was then compared in hepatic cytosol from male mice of three different strains - one with "low' (C3H/HeJ), one with "intermediate' (DBA/2J), and one with "high' (C57BL/6J) hepatic NNMT activity. There were no striking differences among these three strains in hepatic NNMT pH optimum, substrate kinetics, IC50 values for inhibitors, thermal stability or behavior during ion exchange chromatography. The existence of large strain and gender-dependent variation in hepatic NNMT activity will make it possible to use inbred mice for studies of the role of inheritance and gender in the regulation of NNMT activity in this species, as well as for studies of the potential pharmacological and toxicological consequences of variation in this important drug-metabolizing enzyme activity.

Language of Publication

English

Unique Identifier

96252404

MeSH Heading (Major)

Liver|CY/*EN; Methyltransferases|AI/*GE/ME

MeSH Heading

Amodiaquine|ME; Animal; Calcium|ME; Chromatography, Ion Exchange; Enzyme Stability; Female; Human; Hydrogen-Ion Concentration; Kinetics; Magnesium|ME; Male; Mice; Mice, Inbred Strains; Niacinamide|ME; S-Adenosylhomocysteine|ME; S-Adenosylmethionine|ME; Sex Characteristics; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.; Time Factors

Publication Type

JOURNAL ARTICLE

ISSN

0960-314X

Country of Publication

ENGLAND

CAS Registry/EC Number

EC 2.1.1. (Methyltransferases); EC 2.1.1.1 (nicotinamide methyltransferase); 29908-03-0 (S-Adenosylmethionine); 7439-95-4 (Magnesium); 7440-70-2 (Calcium); 86-42-0 (Amodiaquine); 979-92-0 (S-Adenosylhomocysteine); 98-92-0 (Niacinamide)

Record 30 from database: MEDLINE
Return To The Top

Title

Recombinant human phenylethanolamine N-methyltransferase: overproduction in Escherichia coli, purification, and characterization.

Author

Caine JM; Macreadie IG; Grunewald GL; McLeish MJ

Address

Victorian College of Pharmacy, Monash University, 381 Royal Parade, Parkville, Victoria, 3052, Australia.

Source

Protein Expr Purif, 1996 Sep, 8:2, 160-6

Abstract

The gene encoding phenylethanolamine N-methyltransferase (PNMT) has been amplified from a human adrenal medulla cDNA library. Following ligation of the gene into a pET3a-derived expression vector and transformation into Escherichia coli BL21(DE3)pLysS, PNMT was expressed, yielding about 10% of the soluble protein. The enzyme was purified to homogeneity by ammonium sulfate fractionation followed by ion-exchange chromatography and gel filtration. The Km for phenylethanolamine and S-adenosyl-L-methionine were determined to be 130 and 16 microM, respectively. The enzyme could be inhibited by reagents expected to modify cysteine, arginine, tyrosine, and histidine residues, but not by methyl acetimidate, a reagent expected to modify lysine residues.

Language of Publication

English

Unique Identifier

96410778

MeSH Heading (Major)

Phenethanolamine N-Methyltransferase|CH/*GE/IP; Recombinant Proteins|*GE/IP

MeSH Heading

Amino Acid Sequence; Chromatography, Ion Exchange; Cloning, Molecular; Diethyl Pyrocarbonate|PD; DNA Primers; Electrophoresis, Polyacrylamide Gel; Escherichia coli|GE; Gene Expression|GE; Human; Imidoesters|PD; Iodoacetamide|PD; Kinetics; Methyl Methanesulfonate|AA/PD; Molecular Sequence Data; Phenylglyoxal|PD; Plasmids|GE; S-Adenosylmethionine|ME; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.; Tetranitromethane|PD

Publication Type

JOURNAL ARTICLE

ISSN

1046-5928

Country of Publication

UNITED STATES

CAS Registry/EC Number

EC 2.1.1.28 (Phenethanolamine N-Methyltransferase); 0 (DNA Primers); 0 (Imidoesters); 0 (Plasmids); 0 (Recombinant Proteins); 1074-12-0 (Phenylglyoxal); 144-48-9 (Iodoacetamide); 14777-29-8 (methyl acetimidate); 1609-47-8 (Diethyl Pyrocarbonate); 2949-92-0 (methyl methanethiosulfonate); 29908-03-0 (S-Adenosylmethionine); 509-14-8 (Tetranitromethane); 66-27-3 (Methyl Methanesulfonate)

Record 31 from database: MEDLINE
Return To The Top

Title

Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide.

Author

Lysaa RA; Giverhaug T; Wold HL; Aarbakke J

Address

Department of Pharmacology, University of Troms‡, Norway.

Source

Eur J Clin Pharmacol, 1996, 49:5, 393-6

Abstract

RESULTS: Incubation in vitro of human recombinant and erythrocyte (RBC) thiopurine methyl transferase (TPMT) with furosemide, bendroflumethiazide and trichlormethiazide demonstrated inhibition of both enzyme preparations, with IC50 values of 170 microM, 360 microM and 1 mM, respectively. Kinetic studies revealed that the inhibition was mixed or non-competitive with regard both to the thiopurine substrate 6-mercaptopurine (6-MP) and the methyl donor S-adenosyl-L-methionine. CONCLUSION: Since S-methylation is a major pathway in the metabolism of thiopurines, our data point to the possibility of a clinically significant diuretic-thiopurine interaction in patients treated simultaneously with these drugs.

Language of Publication

English

Unique Identifier

97020250

MeSH Heading (Major)

Bendroflumethiazide|AD/*PD; Diuretics|AD/*PD; Furosemide|AD/*PD; Methyltransferases|*AI; Trichlormethiazide|AD/*PD

MeSH Heading

Erythrocytes|DE/EN; Human; In Vitro; Lethal Dose 50; Methylation; Recombinant Proteins|AI; S-Adenosylmethionine|CH/ME; Support, Non-U.S. Gov't; 6-Mercaptopurine|CH/ME

Publication Type

JOURNAL ARTICLE

ISSN

0031-6970

Country of Publication

GERMANY

CAS Registry/EC Number

EC 2.1.1. (Methyltransferases); EC 2.1.1.67 (thiopurine methyltransferase); 0 (Diuretics); 0 (Recombinant Proteins); 133-67-5 (Trichlormethiazide); 29908-03-0 (S-Adenosylmethionine); 50-44-2 (6-Mercaptopurine); 54-31-9 (Furosemide); 73-48-3 (Bendroflumethiazide)

Record 32 from database: MEDLINE
Return To The Top

Title

Expression and purification of a human recombinant methyltransferase that repairs damaged proteins.

Author

MacLaren DC; Clarke S

Address

Department of Chemistry and Biochemistry, University of California, Los Angeles 90095-1569, USA.

Source

Protein Expr Purif, 1995 Feb, 6:1, 99-108

Abstract

We report the construction of a plasmid (pDM2x) containing the coding sequence of the more acidic isozyme II of the human protein-L-isoaspartate (D-aspartate) O-methyltransferase (EC 2.1.1.77) and the overexpression and purification of the recombinant protein. This intracellular enzyme is present in all tissues and can catalyze the first step of a repair reaction where proteins containing abnormal L-isoaspartyl (or D-aspartyl) residues can be converted to forms containing normal L-aspartyl residues. When the methyl-transferase cDNA is expressed in Escherichia coli strain BL21 (DE3) under the T7 phage promoter, we find that active enzyme is produced in amounts up to 20% of the total soluble protein. We have developed a rapid and efficient purification method utilizing a one column-step nonaffinity fractionation that allows for the preparation of 10.2 mg of homogeneous enzyme from 2.6 liters of Luria-Bertani broth culture in less than 24 h. The product is soluble and fully active (10,000 pmol of methyl groups transferred to ovalbumin/mg enzyme/min from S-adenosyl-L-methionine at 37 degrees C). Conditions have been developed to concentrate this enzyme to 30 mg/ml. Analyses of the purified enzyme by N-terminal Edman sequencing and electrospray mass spectroscopy reveal that it is identical to the human isozyme II with the exception that the N-terminal alanine residue is not acetylated.

Language of Publication

English

Unique Identifier

95276476

MeSH Heading (Major)

Protein Methyltransferases|*GE/IP

MeSH Heading

Amino Acid Sequence; Aspartic Acid|ME; Base Sequence; Chromatography, DEAE-Cellulose; Cloning, Molecular; DNA; Escherichia coli|GE; Human; Molecular Sequence Data; Plasmids; Recombinant Proteins|GE; S-Adenosylmethionine|ME; Support, U.S. Gov't, P.H.S.

Publication Type

JOURNAL ARTICLE

ISSN

1046-5928

Country of Publication

UNITED STATES

CAS Registry/EC Number

EC 2.1.1 (Protein Methyltransferases); EC 2.1.1.77 (protein-D-aspartate methyltransferase); 0 (Plasmids); 0 (Recombinant Proteins); 29908-03-0 (S-Adenosylmethionine); 56-84-8 (Aspartic Acid); 9007-49-2 (DNA)

Record 33 from database: MEDLINE
Return To The Top

Title

GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcohol-induced defect.

Author

Fernández-Checa JC; Kaplowitz N; García-Ruiz C; Colell A; Miranda M; Marí M; Ardite E; Morales A

Address

Instituto de Investigaciones Biomédicas, Hospital Clinic i Provincial, Universidad de Barcelona, Spain.

Source

Am J Physiol, 1997 Jul, 273:1 Pt 1, G7-17

Abstract

Mitochondria generate reactive oxygen species (ROS) as byproducts of molecular oxygen consumption in the electron transport chain. Most cellular oxygen is consumed in the cytochrome-c oxidase complex of the respiratory chain, which does not generate reactive species. The ubiquinone pool of complex III of respiration is the major site within the respiratory chain that generates superoxide anion as a result of a single electron transfer to molecular oxygen. Superoxide anion and hydrogen peroxide, derived from the former by superoxide dismutase, are precursor of hydroxyl radical through the participation of transition metals. Glutathione (GSH) in mitochondria is the only defense available to metabolize hydrogen peroxide. A small fraction of the total cellular GSH pool is sequestered in mitochondria by the action of a carrier that transports GSH from the cytosol to the mitochondrial matrix. Mitochondria are not only one of the main cellular sources of ROS, they also are a key target of ROS. Mitochondria are subcellular targets of cytokines, especially tumor necrosis factor (TNF); depletion of GSH in this organelle renders the cell more susceptible to oxidative stress originating in mitochondria. Ceramide generated during TNF signaling leads to increased production of ROS in mitochondria. Chronic ethanol-fed hepatocytes are selectively depleted of GSH in mitochondria due to a defective operation of the carrier responsible for transport of GSH from the cytosol into the mitochondrial matrix. Under these conditions, limitation of the mitochondrial GSH pool represents a critical contributory factor that sensitizes alcoholic hepatocytes to the prooxidant effects of cytokines and prooxidants generated by oxidative metabolism of ethanol. S-adenosyl-L-methionine prevents development of the ethanol-induced defect. The mitochondrial GSH carrier has been functionally expressed in Xenopus laevis oocytes microinjected with mRNA from rat liver. This critical carrier displays functional characteristics distinct from other plasma membrane GSH carriers, such as its ATP dependency, inhibitor specificity, and the size class of mRNA that encode the corresponding carrier, suggesting that the mitochondrial carrier of GSH is a gene product distinct from the plasma membrane transporters.

Language of Publication

English

Unique Identifier

97396313

MeSH Heading (Major)

Alcohol, Ethyl|*PD; Glutathione|*ME; Mitochondria|DE/*ME; Oxidative Stress|*PH; Tumor Necrosis Factor|PD/*PH

MeSH Heading

Animal; Biological Transport; Cytosol|ME; Human; Liver|DE/ME; Mitochondria, Liver|DE/ME; Models, Biological; Rats; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.; Ubiquinol-Cytochrome-c Reductase|ME

Publication Type

JOURNAL ARTICLE; REVIEW; REVIEW, ACADEMIC

ISSN

0002-9513

Country of Publication

UNITED STATES

CAS Registry/EC Number

EC 1.10.2.2 (Ubiquinol-Cytochrome-c Reductase); 0 (Tumor Necrosis Factor); 64-17-5 (Alcohol, Ethyl); 70-18-8 (Glutathione)

Record 34 from database: MEDLINE
Return To The Top

Title

The mammalian immediate-early TIS21 protein and the leukemia-associated BTG1 protein interact with a protein-arginine N-methyltransferase.

Author

Lin WJ; Gary JD; Yang MC; Clarke S; Herschman HR

Address

Molecular Biology Institute, Department of Chemistry and Biochemistry University of California, Los Angeles, 90095, USA.

Source

J Biol Chem, 1996 Jun 21, 271:25, 15034-44

Abstract

The TIS21 immediate-early gene and leukemia-associated BTG1 gene encode proteins with similar sequences. Two-hybrid analysis identified a protein that interacts with TIS21 and BTG1. Sequence motifs associated with S-adenosyl-L-methionine binding suggested this protein might have methyltransferase activity. A glutathione S-transferase (GST) fusion of the putative methyltransferase modifies arginine residues, in appropriate protein substrates, to form NG-monomethyl and NG,NG-dimethylarginine (asymmetric). We term the protein- arginine N-methyltransferase (EC 2.1.1.23) gene "PRMT1, " for protein-arginine methyltransferase 1. GST-TIS21 and GST-BTG1 fusion proteins qualitatively and quantitatively modulate endogenous PRMT1 activity, using control and hypomethylated RAT1 cell extracts as methyl-accepting substrates. PRMT1 message appears ubiquitous, and is constitutive in mitogen-stimulated cells. Modulation of PRMT1 activity by transiently expressed regulatory subunits may be an additional mode of signal transduction following ligand stimulation.

Language of Publication

English

Unique Identifier

96278999

MeSH Heading (Major)

Methyltransferases|*ME; Neoplasm Proteins|BI/CH/*ME; Proteins|BI/CH/*ME

MeSH Heading

Amino Acid Sequence; Animal; Base Sequence; Cloning, Molecular; Comparative Study; DNA Primers; DNA, Complementary; Escherichia coli; Glutathione Transferases|BI; Human; Immediate-Early Proteins|ME; Leukemia, B-Cell, Chronic; Macromolecular Systems; Mammals; Molecular Sequence Data; Open Reading Frames; Polymerase Chain Reaction; Protein Structure, Secondary; Rats; Recombinant Fusion Proteins|BI/ME; Saccharomyces cerevisiae|GD/ME; Sequence Homology, Amino Acid; Support, U.S. Gov't, P.H.S.; Translation, Genetic

Publication Type

JOURNAL ARTICLE

ISSN

0021-9258

Country of Publication

UNITED STATES

CAS Registry/EC Number

EC 2.1.1. (Methyltransferases); EC 2.1.1.- (arginine methyltransferase); EC 2.5.1.18 (Glutathione Transferases); 0 (DNA Primers); 0 (DNA, Complementary); 0 (Immediate-Early Proteins); 0 (Macromolecular Systems); 0 (Neoplasm Proteins); 0 (Proteins); 0 (Recombinant Fusion Proteins); 141490-22-4 (TIS21 protein); 146835-72-5 (BTG1 protein)

Record 35 from database: MEDLINE
Return To The Top

Title

Protein L-isoaspartyl methyltransferase from the nematode Caenorhabditis elegans: genomic structure and substrate specificity.

Author

Kagan RM; Clarke S

Address

Department of Chemistry and Biochemistry, University of California, Los Angeles 90095-1569, USA.

Source

Biochemistry, 1995 Aug 29, 34:34, 10794-806

Abstract

We identified a protein L-isoaspartate (D-aspartate) O-methyltransferase (EC 2.1.1.77) in the nematode worm Caenorhabditis elegans. The methylation of abnormal L-isoaspartyl residues by this enzyme can lead to their conversion to L-aspartyl residues and represents a protein repair step for polypeptides damaged by spontaneous reactions during the aging process. We show that the levels of this enzyme increase 2-fold in C. elegans in the dauer larval form, a developmental stage where the organism can survive for extended periods of time. Utilizing degenerate oligonucleotide primers derived from conserved amino acid sequences of mammalian, plant, and bacterial L-isoaspartyl methyltransferases and PCR amplification, we made DNA probes that allowed us to obtain cDNA and genomic DNA clones encoding this enzyme in the nematode. The deduced amino acid sequence is 53% identical to the human enzyme and 29% identical to the Escherichia coli enzyme. Overexpression of the cDNA for the C. elegans enzyme in E. coli gave an active product with micromolar Km values for L-isoaspartyl-containing peptide substrates and for the methyl donor S-adenosyl-L-methionine. No methylation of D-aspartyl-containing peptides was detected under conditions where the human enzyme catalyzed this reaction, suggesting that the ability to methylate D-aspartyl residues in addition to L-isoaspartyl residues was a later evolutionary adaptation of this enzyme. The C. elegans gene for the methyltransferase, designated pcm-1, was mapped to a single site in a 31 kb region in the central portion of chromosome V. The gene is 3.2 kb in length and includes six introns. Although much smaller, its genomic organization is similar to that of the corresponding mouse gene, with identically positioned intron--exon splice junctions at five of seven sites. We propose that this gene plays an important role in facilitating the long term survival of this organisms.

Language of Publication

English

Unique Identifier

95391655; GENBANK/U09669; GENBANK/U15129

MeSH Heading (Major)

Caenorhabditis elegans|*EN; Genes, Helminth|*; Protein Methyltransferases|CH/*GE/*ME

MeSH Heading

Amino Acid Sequence; Animal; Base Sequence; Cell Survival|GE; Chromosome Mapping; Chromosomes|GE; Cloning, Molecular; Consensus Sequence|GE; Conserved Sequence|GE; DNA Primers; Evolution; Gene Expression; Human; Kinetics; Molecular Sequence Data; Polymerase Chain Reaction; RNA Splicing|GE; Sequence Alignment; Substrate Specificity; Support, U.S. Gov't, P.H.S.

Publication Type

JOURNAL ARTICLE

ISSN

0006-2960

Country of Publication

UNITED STATES

CAS Registry/EC Number

EC 2.1.1 (Protein Methyltransferases); EC 2.1.1.77 (protein-D-aspartate methyltransferase); 0 (DNA Primers)

Record 36 from database: MEDLINE
Return To The Top

Title

DNA modification by methyltransferases.

Author

Cheng X

Address

WM Keck Structural Biology Laboratory, Cold Spring Harbor Laboratory, New York 11724, USA.

Source

Curr Opin Struct Biol, 1995 Feb, 5:1, 4-10

Abstract

Enzymatic methylation of DNA plays important roles in both prokaryotes and eukaryotes. Structural study of the HhaI DNA methyltransferase has provided considerable insight into the chemistry of C5-cytosine methylation. The DNA-protein complex reveals a substrate cytosine flipped out of the double helix during the reaction, and a novel two-loop DNA-binding motif used for both sequence recognition and flipping the base. Structural comparison of HhaI C5-cytosine methyltransferase, TaqI N6-adenine methyltransferase, and catechol O-methyltransferase reveals a common catalytic domain structure, which might be universal among S-adenosyl-L-methionine (SAM)-dependent methyltransferases.

Language of Publication

English

Unique Identifier

95292061

MeSH Heading (Major)

DNA|*CH/*ME; Methyltransferases|CH/*PD; Nucleic Acid Conformation|*DE

MeSH Heading

Amino Acid Sequence; Animal; Human; Molecular Sequence Data; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.

Publication Type

JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

ISSN

0959-440X

Country of Publication

ENGLAND

CAS Registry/EC Number

EC 2.1.1. (Methyltransferases); 9007-49-2 (DNA)

Record 37 from database: MEDLINE
Return To The Top

Title

Involvement of methionine in the synthesis of certain membrane-associated nucleotide sugars by human amnion (WISH) cells.

Author

Wood RC

Address

Department of Microbiology and Immunology, University of Texas, Medical Branch, Galveston, 77555-1019, USA.

Source

Cancer Lett, 1996 Feb 27, 100:1-2, 37-40

Abstract

A plasma membrane preparation from human amnion (WISH) cells contained uridine diphosphate sugars and methyl-uridine diphosphate (mUDP) sugars. The synthesis of mUDP-glucose, mUDP-mannose, and mUDP-fucose by the membrane preparation occurred when supplemented with uridine-5'-diphosphate-glucose and S-adenosyl-L-methionine. It is suggested that this newly recognized route for fucose biosynthesis might be employed by certain transformed cells, and may partly account for the methionine dependence of certain human tumors. Additionally, it is suggested that, in colon cancer, a deficiency of folic acid and methionine might affect mUDP-sugar biosynthesis rather than the methylation of DNA.

Language of Publication

English

Unique Identifier

96196341

MeSH Heading (Major)

Amnion|CY/*ME/UL; S-Adenosylmethionine|*ME; Uridine Diphosphate Sugars|*BI

MeSH Heading

Animal; Cell Membrane|ME; Fucose|BI/ME; Human; Mannose|ME; Mice; Uridine Diphosphate Glucose|BI; 3T3 Cells|ME

Publication Type

JOURNAL ARTICLE

ISSN

0304-3835

Country of Publication

IRELAND

CAS Registry/EC Number

0 (Uridine Diphosphate Sugars); 133-89-1 (Uridine Diphosphate Glucose); 29908-03-0 (S-Adenosylmethionine); 31103-86-3 (Mannose); 3713-31-3 (Fucose)

Record 38 from database: MEDLINE
Return To The Top

Title

Pharmacokinetic profile of Mitoguazone (MGBG) in patients with AIDS related non-Hodgkin's lymphoma.

Author

Rizzo J; Levine AM; Weiss GR; Pearce T; Kraynak M; Mueck R; Smith S; Von Hoff DD; Kuhn JG

Address

Cancer Therapy and Research Center, San Antonio, TX, 78229, USA.

Source

Invest New Drugs, 1996, 14:2, 227-34

Abstract

Mitoguazone is a unique chemotherapeutic agent whose activity is believed to result primarily from the competitive inhibition of S-adenosyl-methionine decarboxylase leading to a disruption in polyamine biosynthesis. Initial clinical trials demonstrated that the dose-limiting toxicities (mucositis and myelosuppression) of Mitoguazone were both dose and schedule dependent. Early pharmacokinetic studies of Mitoguazone in man revealed a prolonged half-life. Concurrent with a recent Phase II trial of Mitoguazone in patients with AIDS related non-Hodgkin's lymphoma, the single dose pharmacokinetics of Mitoguazone were characterized. Twelve patients received 600 mg/m2 of intravenous Mitoguazone over 30 minutes on an intermittent every 2 week schedule. Blood, urine, cerebrospinal fluid (CSF), pleural fluid and tissue samples were collected and analyzed by HPLC. Mitoguazone was cleared from the plasma triexponentially with a harmonic mean terminal half-life of 175 hours and a mean residence time of 192 hours. Peak plasma levels occurred immediately post-infusion, ranged from 6.47 to 42.8 micrograms/ml, and remained (for an extended period) well above the reported concentration for inhibition of polyamine biosynthesis. Plasma clearance averaged 4.73 l/hr/m2 with a relatively large apparent volume of distribution at steady-state of 1012 l/m2 indicating tissue sequestration. Renal excretion of unchanged Mitoguazone accounted for an average of 15.8% of the dose within 48 to 72 hours post-administration. Detectable levels of drug were present in random voided samples eight days post-dose. Mitoguazone levels in CSF ranged from 22 to 186 ng/ml post-dose with CSF/plasma ratios ranging from 0.6% to 7%. The pleural fluid/plasma ratio was approximately 1. Tissue levels of Mitoguazone were highest in the liver followed by lymph node, spleen and the brain.

Language of Publication

English

Unique Identifier

97070920

MeSH Heading (Major)

Antineoplastic Agents|*PK/*TU; Lymphoma, AIDS-Related|*DT/*ME; Mitoguazone|*PK/*TU

MeSH Heading

Adult; Human; Male; Middle Age; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.

Publication Type

CLINICAL TRIAL; CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE

ISSN

0167-6997

Country of Publication

UNITED STATES

CAS Registry/EC Number

0 (Antineoplastic Agents); 459-86-9 (Mitoguazone)

Record 39 from database: MEDLINE
Return To The Top

Title

Treatment of nude mice with 4-amidinoindan -1- one2 '- amidinohydrazone, a new S-adenosylmethionine decarboxylase inhibitor, delays growth and inhibits metastasis of human melanoma cells.

Author

Gutman M; Beltran PJ; Fan D; Delworth MG; Singh RK; Wilson MR; Fidler IJ

Address

Department of Cell Biology, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.

Source

Melanoma Res, 1995 Jun, 5:3, 147-54

Abstract

CGP 48664A (4-amidinoindan-1-one2'-amidinohydrazone) is a novel inhibitor of S-adenosyl-methionine decarboxylase (SAMDC), a key enzyme in the biosynthesis of polyamines, which are themselves essential for proliferation of mammalian cells. Seven different human melanoma cell lines were treated in vitro with CGP 48664A. High, intermediate and low levels of cytostasis were induced in four, one and two melanoma lines, respectively. This cytostasis was reversed by the addition of exogenous spermidine or spermine to the culture medium. The heterogeneous low metastatic (CGP 48664A-resistant) A375P cells and highly metastatic (CGP 48664A-sensitive) A375SM cells were implanted into the subcutis or injected intravenously into nude mice. Systemic daily administration of CGP 48664A significantly reduced the size of cutaneous lesions and the number of lung metastases in mice implanted with A375SM cells. No beneficial effects were found in mice injected with A375P cells. Drug activity was dose dependent, and maximal effects were observed when treatment began in mice with small tumour burdens. The data suggest that CGP 48664A is effective against melanoma metastasis in nude mice and that its activity should be tested in combination with other cytoreductive agents.

Language of Publication

English

Unique Identifier

95367845

MeSH Heading (Major)

Amidines|*PD; Indans|*PD; Melanoma|DT/PA/*SC; S-Adenosylmethionine Decarboxylase|*AI/ME

MeSH Heading

Animal; Cell Division|DE; Culture Media; Dose-Response Relationship, Drug; Human; Lung Neoplasms|PA/SC; Male; Mice; Mice, Nude; Neoplasm Transplantation; Spermidine|PD; Spermine|PD; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.; Tumor Cells, Cultured

Publication Type

JOURNAL ARTICLE

ISSN

0960-8931

Country of Publication

ENGLAND

CAS Registry/EC Number

EC 4.1.1.50 (S-Adenosylmethionine Decarboxylase); 0 (Amidines); 0 (Culture Media); 0 (Indans); 124-20-9 (Spermidine); 149400-88-4 (4-amidinoindan-1-one 2'-amidinohydrazone); 71-44-3 (Spermine)

Record 40 from database: MEDLINE
Return To The Top

Title

Activation-dependent carboxyl methylation of neutrophil G-protein gamma subunit.

Author

Philips MR; Staud R; Pillinger M; Feoktistov A; Volker C; Stock JB; Weissmann G

Address

Department of Medicine, New York University Medical Center, NY 10016.

Source

Proc Natl Acad Sci U S A, 1995 Mar 14, 92:6, 2283-7

Abstract

The gamma subunits of heterotrimeric guanine nucleotide-binding regulatory (G) proteins (G gamma) are post-translationally processed at their C termini by prenylation, proteolysis, and carboxyl methylation. Whereas prenylation of G gamma is required for membrane association of G proteins, the role of carboxyl methylation is unknown. Here we show that human neutrophils express G gamma 2 but not G gamma 3 or G gamma 7 and that carboxyl methylation of G gamma 2 is associated with signal transduction. In a reconstituted cell-free system, neutrophil G gamma 2 was labeled by the methyl donor S-[methyl-3H]adenosyl-L-methionine. Carboxyl methylation was confirmed by alkaline hydrolysis and quantitation of volatile [3H]methanol. Neutrophil G gamma 2 methylation was stimulated by activation of G protein with guanosine 5'-[beta, gamma-thio]triphosphate. We estimate that after 1 hr of G-protein activation at least 6% of the total pool of G gamma 2 was carboxyl-methylated. The inflammatory agonist fMet-Leu-Phe stimulated guanosine 5'-[beta,gamma-thio]triphosphate-dependent carboxyl methylation. Methylation of G gamma 2 was inhibited by the carboxyl methyltransferase inhibitor N-acetyl-S-trans,trans-farnesylcysteine at concentrations that affected signal transduction in neutrophils. These results demonstrate that activation of neutrophil Gi is associated with alpha-carboxyl methyl esterification of G gamma 2 and suggest that carboxyl methylation of G gamma may play a role in signal transduction.

Language of Publication

English

Unique Identifier

95199335

MeSH Heading (Major)

G-Proteins|IP/*ME; Neutrophils|DE/*ME/PH; S-Adenosylmethionine|*ME

MeSH Heading

Antibodies; Electrophoresis, Polyacrylamide Gel; Guanine Nucleotides|PD; Human; Immunoblotting; In Vitro; Iodine Radioisotopes; Macromolecular Systems; Methylation; Molecular Weight; N-Formylmethionine Leucyl-Phenylalanine|PD; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.; Tritium

Publication Type

JOURNAL ARTICLE

ISSN

0027-8424

Country of Publication

UNITED STATES

CAS Registry/EC Number

0 (Antibodies); 0 (G-Proteins); 0 (Guanine Nucleotides); 0 (Iodine Radioisotopes); 0 (Macromolecular Systems); 10028-17-8 (Tritium); 29908-03-0 (S-Adenosylmethionine); 59880-97-6 (N-Formylmethionine Leucyl-Phenylalanine)

[ Home ] [ Up ] [ Dr. Scott M. Grundy ] [ Methionine ] [ Summary And Link Page for data about The Amino Acid Ornithine ] [ SAM --S-adenosyl methionine Research Reports ] [ Phenylalanine ] [ Summary And Link Page for data about The Amino Acid Arginine ]

SUBSCRIBE:  The Wednesday Letter is a free electronic monthly newsletter written and published by Karl Loren.  You can view more than 50 back issues of this publication by clicking here.  The Wednesday Letter subscription list is maintained on a secure server, no name is ever given or sold to anyone, and it is never used except for this Newsletter.  It is automatically published on the Tuesday night just before the first Wednesday of every month.  You can subscribe to this free monthly electronic letter by entering your eMail address and name below.  You will then automatically receive a request for confirmation, sent to whatever address you have entered.  If you do NOT receive this confirmation request, then you will not be subscribed.  There may have been an error with your address and you should resubmit.  The letter is never sent twice to the same address -- so you do not have to worry about a duplicate subscription.  When you receive this confirmation request you must reply to it, or your subscription will not become active.  No one can subscribe your name, and address, without you being notified, and if you get an unwanted notice of subscription you only need to DO NOTHING and the subscription will NOT be active.

REMOVAL:  You can remove yourself from the subscription list in several different ways.  Click here to read about this entire newsletter system.  Every edition of The Wednesday Letter is delivered to your address with YOUR name and address in view on the letter, with a link that allows you to remove THAT name from the subscription list.  If you try to send this removal message from an address different from the one you used to send in your original confirmation, then you will get a warning notice first, sent to the subscription address, asking you to confirm that you want to be removed from the list -- by replying to THAT request for confirmation, you will then be automatically removed.  Thus, no one else can unsubscribe you, from some other computer, without your knowledge.  But, if you send in the unsubscribe notice from the same machine used to receive the Letter, then the removal from the subscription list is automatic.

Personal Message:  When you send a personal message to Karl Loren, you will receive a personal reply as per his instructions.  Karl pledges that every personal message will get a personal answer. When you provide your mail address, we will send you free information including our free catalog and a cassette tape lecture by Karl Loren about heart disease, no charge, by mail, even if outside the US.  You can select particular information you would like to receive, along with the free cassette tape and catalog.

You can reach Vibrant Life in many ways, including by mail to Vibrant Life, 2808 N. Naomi St., Burbank, CA 91504.  Within the US and Canada, use the toll free number:  (800) 523-4521, the local number:  (818) 558-1799, the FAX:  (818) 558-7299, eMail to kimberly@oralchelation.com or any one of the hundreds of message forms throughout the 50 web sites.  Vibrant Life normally ships the same day we get an order.  There are message forms on each of the 100,000+ pages on this and other sites where you can communicate with Vibrant Life.  Check out our companion site, at:  http://www.oralchelation.net where Karl's 2000 page book is published.  Karl Loren is the author and webmaster for this BOOK, as well as for another web site about ORAL CHELATION.  His personal philosophical articles are at PHILOSOPHY. 

Copyright © May 20, 2008 6:24 AM by Karl Loren on behalf of Vibrant Life, ALL RIGHTS RESERVED.  Permission is granted for non-commercial downloading, copying, distribution or redistribution on two conditions:  One, that some form of copyright notice is included in every copy distributed or copied, showing the copyright belonging to Vibrant Life, Burbank, CA, at www.oralchelation.com . The second condition is that the material is not to be used for any purpose contrary to the purposes and objectives of this site.  This permission does not extend to materials on this site which are copyrighted by others.